書籍詳細

2. 腫瘍抗原

P.7 掲載の参考文献

• 1) 日本免疫学会(編) :免疫実験操作法, A. 日本免疫学会, 1978.

• 2) 日本免疫学会(編) :免疫実験操作法, B. 日本免疫学会, 1978.

• 3) Gaylord, H. R. and Clows, G. H. A.:Spontaneous regression of cancer. Gynec. Obstet, 2:633-639, 1903.

• 4) Aberev, G. I., Perova, S. D., Khramkova, N. I., Postnikova, Z. A. and Irlin, I. S.:Production of embryonal α-globulin by transplantable mouse hepatomas. Transplantation, 1:174-180, 1963.

• 5) Klein, G., Sjogren, H. O. and Klein, E.:Demonstration of host resistance against sarcomas induced by implantation of cellophane films in isologous recipients. Cancer Res, 23:84-92, 1963.
  pubmed

• 6) Old, L. J., Boyse, E. A. and Stockert, E.:Antigenic properties of experimental leukemias. J. Natl. Cancer Inst., 31:977-986, 1963.

• 7) Yoshida, T.:Zellulare Multizentrizitat der Krebsentstehung. Deutsch Med. Wochschr., 88:2229-2238, 1963.

• 8) Tatarinov, J.:Detection of embryospecific α-globulin in the blood of patients with primary liver tumors. Vopn. Med. Klin., 10:90-91, 1964.

• 9) Everson, R. C. and Cole, W. H.:Spontaneous regression of cancer. Saunders Company, Philadelphia, 1966.

• 10) Rosenau, W. and Morton, D. L.:Tumor-specific inhibition of growth of methylcholanthrene-induced sarcomas in vivo and in vitro by sensitized isologous lymphoid cells. J. Natl. Cancer Inst., 36:825-836, 1966.

• 11) Takeda, K., Kikuchi, Y., Yamawaki, S., Ueda, T. and Yoshiki, T.:Treatment of artificial metastases of methylcholanthrene-induced rat sarcomas by autoimmunization of the autochthonous hosts. Cancer Res., 28:2149-2154, 1968.
  pubmed

• 12) Takemoto, K. K., Ting, R. C. Y., Ozer, H. L. and Fabish, P.:Establishment of a cell line from an inbred mouse strain for transformation studies:Simian virus 40 transformation and tumor production. J. Natl. Cancer Inst., 41:1401-1409, 1969.

• 13) Coggin, J. H., Ambrose, K. R. and Anderson, N. G.:Fetal antigen capable of inducing transplantation immunity against SV40 hamster tumor cells. J. Immunol., 105:525-529, 1970.

• 14) Taylor, R. B., Duffus, W. P. H., Raff, M. C. and de Petris, S.:Redestribution and pinocytosis of limphocytes surface immunoglobulin molecules induced by anti-immunoglobulin antibody. Nature New Biol., 223:317-321, 1971.

• 15) Baldwin, R. W., Price, M. R. and Robins, R. A.:Blocking of lymphocytes-mediated cytotoxicity for rat hepatoma cells by tumorspecific antigen antibody complexes, Nature New Biol., 238:185-187, 1972.

• 16) Bartlet, G. L.:Effect of host immunity on the antigenic strength of primary tumors. J. Natl. Cancer Inst., 49:493-504, 1972.

• 17) Baldwin, R. W.:Immunological aspects of chemical carcinogenesis Adv. Cancer Res., 18:1-75, 1973.
  pubmed

• 18) Fidler, I. J.:Selection of successitive tumor lines for metastasis. Nature New Biol., 242:148-150, 1973.
  pubmed

• 19) Kobayashi, H., Kuzumaki, N., Gotohda, E., Takeichi, N., Sendo, F., Hosokawa, M. and Kodama, T.:Specific antigenicity of tumors and immunological tolerance in the rat induced by Friend, Gross and Rauscher viruses. Cancer Res., 33:1598-1603, 1973.

• 20) Kodama, T., Gotohda, E. and Kobayashi H.:Immunoelectron microscopic studies on surface antigens of rat tumor cells infected with Friend virus. Gann, 64:475-479, 1973.
  pubmed

• 21) Kodama, T., Takeichi, N., Gotohda, E. and Kobayashi, H.:Electron microscopic studies on sialoglycoprotein layer of rat Friend tumor cells. Gann, 64:613-616, 1973.

• 22) Ishidate, M.:Antigenic spicificity of different cell lines of rat ascites hepatoma originating in the same individual. Gan Monograph of Cancer Res., 16:195-210, 1974.

• 23) Kersey, J. H., Gajl-Peczalska, K. J. and Nebit, M. E.:The lymphoid systems;abnormalities in immunodeficiency and malignancy. J. Pediat., 84:789-795, 1974.

• 24) Doljanski, F. and Kappeller, M.:Cell surface shedding the phenomenon and ist possible significance. J. Theor, Biol., 62:253-270, 1976.

• 25) Law, L. L. and Appella, E.:Studies of soluble transplantation antigens. In Cancer, ed. by Becker, F. F., Plenum Press, New York, Vol. 4:135-157, 1975.

• 26) Parmiani, G. and Invernizzi, G.:Alien histocompatibility determinants on the cell surface of sarcomas induced by methylcholanthrene. I. In vivo studies. Int. J. Cancer, 16:756-767, 1975.
  pubmed

• 27) Simmons, R. L. and Rios, A.:Comparative immunotherapeutic effect of concanavalin A and neuraminidase-treated cancer cells. Transplantation. Proc., 7:247-251, 1975.
  pubmed

• 28) Tevethia, S. S. and Tevethia, M. J.:DNA virus (SV40) induced antigens. In Cancer, ed. by Becker, F. F., Plenum Press, New York, Vol. 4:185-207, 1975.

• 29) Kripke, M. L. and Fischer, M. S.:Immunologic responses of the autochthonous host against tumors induced by ultraviolet light. Adv. Exp. Med. Biol., 66:445-449, 1976.

• 30) Baldwin, R. W.:Tumor-associated antigens. Z. Krebsforsh., 89:1-8, 1977.
  pubmed

• 31) Heppner, G. H., Dexter, D. L. and Miller, F. R.:Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res., 38:3758-3763, 1978.
  pubmed

• 32) Stackpole, C. W. and Jacobson, J. B.:Antigenic modulation. In The Handbook of Cancer Immunology, ed. by Waters, H., Garland STPM Press, New York & London, Vol. 2:55-159, 1978.

• 33) Kobayashi, H. (ed.) :Immunological Xenogenization of Tumor Cells. GANN Monogr. Cancer Res., Japan Scientific Societies Press, Tokyo, No. 23, 1979.

• 34) Kodama, T.:Lateral mobility and stabilized expression of tumorassociated surface antigen in xenogenized tumor cells. In GANN Monogr. Cancer Res., ed. by Kobayashi, H., Japan Scientific Societies Press, Tokyo, No. 23:57-63, 1979.

3. 分化関連抗原

P.28 掲載の参考文献

• 1) 西 信三, 平井秀松:CEA (Carcinoembryonic antigen) の測定法. 臨床病理臨時特集 25:55-68, 1976.

• 2) 佐藤清美:アイソザイムのガン胎児性変異, 特にグリコーゲンホスホリラーゼについて. 生化学, 49:1091-1119, 1977.

• 3) 平井秀松:抗体抗原, Carcino-embryonic antigen. 総合臨床, 27:2437-2446, 1978.

• 4) 東野一彌, 波田寿一:癌とアルカリホスファターゼ. 代謝, 16:215-223, 1979.

• 5) 新津洋司郎:腫瘍マーカーIsoferritin. 臨床科学, 16:857-862, 1980.

• 6) 西 信三:Alpha-fetoprotein (AFP) , 基礎の立場から. 臨床科学, 16:793-800, 1980.

• 7) 平井秀松:癌胎児共通表現形質. 代謝, 17, 8月臨時増刊:211-228, 1980.

• 8) Bodmer, W. F.:A new model for allelism at histocompatibility and other complex loci.:Polymorphism for control of gene expression. Transplant. Proc., 5:1471-1475, 1973.
  pubmed

• 9) Martin, W. J., Esber, E., Cotton, W. G. and Rice, J. M.:Derepression of alloantigens in malignancy:Evidence for tumor susceptibility alloantigens and for possible self-reactivity of lymphoid cells active in the microcytotoxicity assay. Br. J. Cancer, 28:(Suppl. I) :48-61, 1973.

• 10) Martin, M. J.:Immune surveillance directed against derepressed cellular and viral alloantigens. Cell. Immunol., 15:1471-1475, 1975.

• 11) Parmiani, G., and Invernizzi, G.:Alien histocompatibility determinants on the cell surface of sarcomas induced by methylcholanthrene. I. In vivo studies. Int. J. Cancer, 16:756-767, 1975.
  pubmed

• 12) Zinkernagel, R. M. and Doherty, P. C.:H-2 compatibility requirement for T cell meditated lysis of target cells infected with lymphocyte choriomeningitis virus. Different cytotoxic T cell specificities are associated with structures coded for in H-2K or H-2D. J. Exp. Med., 141:1427-1436, 1975.
  pubmed

• 13) Garrido, F., Schirrmacher, V. and Festenstein, H.:H-2 like specificities of foreign haplotypes appearing on a mouse sarcoma after vaccimia infection. Nature, 259:228-230, 1976.
  pubmed

• 14) Martin, W. J., Gipson, T. G., Martin, S. E. and Rice, J. M.:Derepressed alloantigen on transplacentally induced lung tumor coded for by H-2 liked gene. Science, 194:532-533, 1976.

• 15) Wrathmell, A. B., Gauci, G. L. and Alexander, P.:Cross reactivity of an alloantigen present on normal cells with the tumor specific transplantaion antigen of the acute myeloid leukemia (SAL) of rats. Br. J. Cancer, 33:187-184, 1976.

• 16) Martin, W. J., Gipson, T. G., Conliffe, M. A., Fridman, R. J., Dove, L. and Rice, J. M.:Common tumor-associated transplantation alloantigen detected on a proportion of lung tumors induced transplacentally in several strains of mice. Transplantation, 24:294-296, 1977.

• 17) Meschini, A., Invernizzi, G. and Parmiani, G.:Expression of alien H-2 specificities on a chemically induced BALB/c fibrosarcoma, Int. J. Cancer, 20:271-283, 1977.

• 18) Gipson, T. G., Imamura, M., Conliffe, M. A. and Martin, W. J.:Lung tumor-associated alloantigen coded for by the K region of the H-2 major histocompatibility complex. J. Exp. Med., 147:1363-1373, 1978.

• 19) Jan Klein:H-2 mutations:Their genetics and effect on immune fanctions. Adv. Immunol., 26:54-141, 1978.

• 20) Meschini, A. and Parmiani, G.:Anti-H-2 alloantibodies elicited by a syngeneic immunization with a chemically induced fibrosarcoma. Immunogenetics, 6:117-123, 1978.

• 21) Parmiani, G., Meschini, A., Invernizzi, G., and Carbone, G.:Tumor associated transplantation antigen distinct from H-2k-like antigens on a BALB/c (H-2d) fibrosarcoma. J. Natl. Cancer Inst., 61:1229-1234, 1978.

• 22) Imamura, M., Gipson, T. G., Bensky, N., Justice, R. and Martin, W. J.:Lung tumor reactive cytotoxic lymphocytes generated in mixed lymphocyte culture between C3HfeB/HeN (H-2kb) and C3H/HeN(H-2k) strain mice. J. Immunol., 123:1863-1866, 1979.

• 23) Rogers, M. J., Appella, E., Pierotti, M. A., Invernizzi, G. and Parmiani, G.:Biochemical characterization of alien H-2 antigens expressed on a methylchoranthrene-induced tumor. Proc. Natl. Acad. Sci., 76:1415-1419, 1979.

• 24) Ruoslahti, E. and Seppala, M.:Adv. Cancer Res., 29:275-346 1979.
  pubmed

• 25) Alexander, P., Denham, S. and Hooton, J.:On the nature of the antigen (Ho-SAL) responsible for protection of August rats against a syngeneic leukemia following immunization with AgB-identical allogeneic cells. Transplant. Proc., 12:152-155, 1980.
  pubmed

• 26) Bonavida, B., Roman, J. M. and Hutchinson, I. V.:Inappropriate alloantigen-like specificities detected on reticulum cell sarcomas of SJL/J mice:Characterization and biologic role. Transplant. Proc., 12:59-64, 1980.
  pubmed

• 27) Finke, J. H., Fyfe, D. A., Del Villano, B. C., Butler, G. H. and Ponzio, N. H.:Characterization of "foreign" alloantigen-like specificities on a murine lymphoma cell lines. Transplant. Proc., 12:53-58, 1980.
  pubmed

• 28) Greene, M. I. and Perry, L. L.:The relationship of alloreactivity to syngeneic tumor immunity. Transplant. Proc., 12:80-86, 1980.
  pubmed

• 29) Imamura, M. and Martin, W. J.:Variable expression and immunogenicity of an H-2K-coded alloantigen on murine tumours. J. Immunogenet., 7:31-37, 1980.

• 30) McAlack, R. F.:Normal HLA phenothypes and neo-HLA-like antigens on cultured human neuroblastoma. Transplant. Proc., 12:107-113, 1980.

• 31) Schimidt, W. and Festenstein, H.:Serological and immunochemical studies of allospecificities on K36, a syngeneic lymphoma of AKR. J. Immunogenet. 7:7-17, 1980.

• 32) Schirrmacher, V., Garrido F., Garcia-Olivares, F., Perez, M. and Torres, M. D.:Expression of foreign H-2 like antigens by a chemically induced murine tumor (MCG4) . J. Immunogenet., 7:51-59, 1980.
  pubmed

4. 誘発抗原

P.42 掲載の参考文献

• 1) 中村恭二:ラットのメチルコラントレン肉腫の抗原共通性. 癌の免疫病理, 3:28-35, 1967.

• 2) 菊地浩吉:癌組織におけるリンパ系反応, 人癌と免疫 (藤井源七郎編) . ライフサイエンス社, pp. 67-73, 1976.

• 3) Foley, E. J.:Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res., 13:835-843, 1953.
  pubmed

• 4) Huebner, R. J., Rowe, W. P., Turner, H. C. and Lane, W. T.:Specific adenovirus complement-fixing antigens virus-free hamster and rat tumors. Proc. Natl. Acad. Sci., USA, 50:379-389, 1963.
  pubmed

• 5) Maisin, J. H. F.:Immunoprophylaxis of induced experimental hepatoma. Nature, 202:202-203, 1964.

• 6) Sjogren, H. O.:Transplantation methods as a tool for detection of tumor specific antigens. Progr. Expr. Tumor Res., 6:289-322, 1965.

• 7) Tevethia, S. S., Katz, M., and Rapp, F.:New surface antigens in cells transformed by simian papovavirus SV40. Proc. Soc. Expr. Biol., 119:896-899, 1965.

• 8) Baldwin, R. W.:Tumor specific immunity against spontaneous rat tumors. Int. J. Cancer, 1:257-263, 1966.
  pubmed

• 9) Reiner, J. and Southam, C. M.:Evidence of common antigenic properties in chemically induced sarcomas of mice. Cancer Res., 27:1243-1247, 1967.
  pubmed

• 10) Vaage, J.:Non-cross-reacting resistance to virus-induced mouse mammary tumors in virus-infected C3H mice. Nature, 218:101-103, 1968.
  pubmed

• 11) Zbar, B., Wepsic, H. T., Rapp, H. J., Borsos, T., Kronman, B. S. and Churchill, W. H.:Antigenic specificity of hepatomas induced in strain-2 guinea pigs by diethylnitrosoamine. J. Natl. Cancer Inst., 43:833-842, 1969.

• 12) Outzen, H. C., Andrews, E. J., Basombrio, M. A., Litwin, S., and Prehn, R. T.:Attempted induction of tumor antigen in carcinogen-treated cells. J. Natl. Cancer Inst., 49:1295-1302, 1972.

• 13) Whitmire, C. E. and Huebner, R. J.:Inhibition of chemical carcinogenesis by viral vaccines. Science, 177:60-61, 1972.
  pubmed

• 14) Baldwin, R. W.:Immunological aspects of chemical carcinogenesis. Adv. Cancer Res., 18:1-75, 1973.
  pubmed

• 15) Brand, G.:Foreign body induced sarcomas. In Cancer, ed. by Becker, F. F., Plenum Press, New York, Vol. 1:485-511, 1975.

• 16) Tevethia, S. S. and Tevethia, M. J.:DMA virus (SV40) induced antigens. In Cancer, ed. by Becker, F. F., Plenum Press, New York, Vol. 4:185-207, 1975.

• 17) Hewitt, H. B., Blake, E. R. and Walder, A. S.:A critique of the evidence for active host defence against cancer, besed on personal studis of 27 murine tumors of spontaneous origin. Br. J. Cancer, 33:241-259, 1976.

• 18) Anderson, J. L., Martin, R, G., Chang, C., Mora, P. T. and Livingston, D. M.:Nuclear preparations of SV-40-transformed cell contain tumor-specific transplantation antigen activity. Virology, 76:420-425, 1977.
  pubmed

• 19) Kripke, M. L., Lofgreen, J. S., Beard, J., Jessup, J. M. and Fisher, M. S.:In vivo immune responses of mice during carcinogenesis by ultraviolet irradiation. J. Natl. Cancer Inst., 59:1227-1230, 1977.
  pubmed

• 20) Pimm, M. V. and Baldwin, R. W.:Antigenic differences detween primary methylcholanthrene-induced rat sarcomas and post surgical recurrences. Int. J. Cancer, 20:41-45, 1977.

• 21) Siegert, W., Fenyo, E. M. and Klein, G.:Separation of the Moloney leukemia virus-determined cell surface antigen (MCSA) from known virion proteins associated with the cell membrane. Int. J. Cancer, 20:75-82, 1977.
  pubmed

• 22) Coggin, J. H.:Cancer:the produce of abortive redifferentiation. In Immunological Aspects of Cancer, ed. by Castro, J. E., MTP Press, Inc., pp. 89-100, 1978.

• 23) Hellstrom, I. and Hellstrom, K. E.:Cyclophosphamide delays 3-methyl-cholanthrene sarcoma induction in mice. Nature, 275:129-130, 1978.

5. 動物の腫瘍特異抗原

P.56 掲載の参考文献

• 1) 名取 孝, 相沢幹:腫瘍特異的移植抗原の物性に関する研究の概況. 医学のあゆみ, 105:861, 1978.

• 2) 山岸久一, Pellis N. R. and Kahan B. D.:メチールコラントレン誘発腫瘍抗原(TSTA) の解析. isoelectric focusingによるtumor-facilitating antigenとtumor-protective antigenの分画, 医学のあゆみ. 109:432-434 1979.

• 3) Nathenson, S. G.:Biochemical properties of histocompatibility antigens. Ann. Rev. Genetics, 4:69, 1970.

• 4) Reisfeld, R. A.:Transplantation antigens. Adv. Immunol., 12:117, 1970.
  pubmed

• 5) Law, L. W. and Appella, E.:Immunogenic properties of solublized tumour antigen from an RNA virus-transformed neoplasm. Nature, 243:83, 1973.

• 6) Helenius, A. and Simons, K.:Solubilization of membranes by detergents. Biochim. Biophysic. Acta., 415:29, 1975.

• 7) Meltzer, M. S., Leonard, E. J. et al.:Protective tumor immunity induced by potassium chloride extracts of guinea pig hepatomas. J. N. C. I., 54:1349, 1975.

• 8) Clemetson, K. J., Gerber, A. et al.:Solubilization of histocompatibility and tumor-associated antigens of the P-815 murine mastocytoma cell. Europ. J. Cancer, 12:263, 1976.

• 9) Pellis, N. R., Shulan, D. J. and Kahan, B. D.:Ppecific tumor immunity induced with soluble materials:purification of antigens inducing tumor resistance. Biochem. Biophys. Res. Commun., 71:1251, 1976.
  pubmed

• 10) Henriksen, O., Law, L. W. and Appella, E.:Ouantitative in vivo studies of soluble SV-40 tumor specific transplantation antigens (TSTA) of the mouse. J. N. C. I. 58:1785, 1977.

• 11) Invernizzi, G., Carbone, G. et al.:Multiple foreign non-H-2 determinants on the surface of a chemically-induced murine sarcoma. J. Immunogenetics, 4:97, 1977.

• 12) Klein, G.:Tumor-associated antigens in H-2 hemizygous isoantigenic variants of a somatic cell hybrid derived from the fusion of a 3-methylcholanthrene-induced sarcoma and a mammary carcinoma. J. N. C. I., 58:383, 1977.

• 13) Matsuo, T., Nishi, S. et al.:Studies on Epstein-Barr virus related antigens. II. Biochemical properties of soluble antigen in Raji Burkitt lymphoma cells. Int. J. Cancer, 19:364, 1977.

• 14) Natori, T., Law, L. W. and Appella, E.:Biological and biochemical properties of Nonidet P40-solubilized and partially purified tumor-specific antigens of transplantation type from plasma membranes of a methylcholanthrene-induced sarcoma. Cancer Res., 37:3406, 1977.
  pubmed

• 15) Natori, T., Law, L. W. and Appella, E.:Biologic and biochemical properties of detergent-solubilized tumor specific transplantation antigen from a simian virus 40-induced neoplasm. J. N. C. I., 59:1331, 1977.

• 16) Rogers, M., Law, L. W., et al.:Solubilized TSTA and the major structural proteins, gp70 and p30, in the immune response to murine leukemias induced by Friend and Rauscher virus. Int. J. Cancer, 20:303, 1977.
  pubmed

• 17) Fiers, W., Contreras, R. et al.:Complete nucleotide sequence of SV 40 DNA. Nature, 273:113, 1978.
  pubmed

• 18) Luborsky, S. W., Chang, C. et al.:Comparative behavior of simian virus 40 T-antigen and of tumor specific surface and transplantation antigens during partial purification. Cancer Res., 38:2367, 1978.
  pubmed

• 19) Natori, T., Law, L. W and Appella, E.:Immunocheimcal eviedence of a tumor-specific surface antigen obtained by detergent solubilization of the membranes of a chemically induced sarcoma, Meth-A. Cancer Res., 38:359, 1978.

• 20) Rigby, P.:The transforming genes of SV 40 and polyoma, Nature, 282:781, 1979.
  pubmed

6. ヒトの腫瘍特異抗原

P.71 掲載の参考文献

• 1) 山村雄一, 桜井欽夫, 木村禧代二 (監修) :人癌と免疫. (藤井源七郎他編) ライフサイエンス, 1976.

• 2) 珠玖洋, 高橋利忠:ヒトの癌細胞抗原. 代謝, 15:157-160, 1978.

• 3) Castro, J. E. (ed.) :Immunological Aspects of Cancer. MTP Press, Lancaster, 1978.

• 4) Waters, H. (ed.) :The Handbook of Cancer Immunology. Garland STPM press, New York and London, 1978.

7. 腫瘍特異抗原性の上昇

P.82 掲載の参考文献

• 1) Apffel, C. A., Arnason, B. G. and Peters, J. H.:Induction of turmor immunity with tumos cells treated with iodoacetate Nature, 209, 694, 1966.

• 2) Lin, J. S. L., Huber, N. and Murphy, W. H.:Immunization of C58 mice to line Ib leukemia. Cancer Res., 29:2157, 1969.

• 3) Watkins, J. F. and Chen, L.:Immunization of mice against Ehrlich ascites tumor using a hamster/Ehrlich ascites tumor hyhrid cell lines. Nature, 223:1018, 1969.

• 4) Braun, W., Plescia, O. L., Paskova, J. and Wehl D.:Basic proterins and synthetic polynucleotides as modifiers of immunogenicity of syngeneic tumor cells. Israel J. Med. Sci., 7:72, 1971.

• 5) Prager, M. D. Baechtel, F. S., Ribble, R. J., Ludden, C. M. and Mehta, J. M.:Immunological stimulation with modified lymphoma cells in a minimally responsine tumorhost system. Cancer Res., 34:3203, 1974.

• 6) Frost, P. and Sanderson, C. J.:Tumor immunoprophyloxis in mice using glhtaraldehyde-treated syngeneic tumor cells. Cancer Res., 35:2646, 1975.

• 7) Invernizzi, G. and Parmiani, G.:Tumor-associated transplantation antigens of chemically induced sarcomata cross-reacting with allogeneic histocompatibility antigens Nature, 254:713, 1975.
  pubmed

• 8) Lachman, P. J. and Sikara, K.:Coupling PPD to tumor cells enhances their antigenicity in BCG-primed mice. Nature, 271:463, 1978.

• 9) Prager, M. D. and Gordon, W. C.:Enhanced response to chemoimmunotherapy and immunoprophyloxis using tumor associated antigens with a lipophilic agent. Cancer Res., 38:2052, 1978.

• 10) Sendo, F., Miyake, T., Fuyama, S. and Arai, S.:Spontaneous regression of syngeneic transplanted tumor in rats pretreated with the antileukemia drug busulfan. J. Natl Cancer. Inst., 60:385, 1978.
  pubmed

• 11) Takatsu, K., Tominaga, A. and Late Kitagawa, M.:Induction of antitumor activity in mice presansitized with Mycobacterium by immunization with tuberculin-coated tumor. Gann, 69:597, 1978.

• 12) Takeichi, N., Austin, F. C., Oikawa, T. and Boone, C. W.:Augmented immunogenicity of tumor cell membranes produced by infection with influenza virus as compared to Moloney sarcoma virus. Cancer Res., 38:4580, 1978.
  pubmed

• 13) Baldwin, R. W. and Byers, V. S.:Immunoregulation by bacterial organisms and their role in the immunotherapy of Cancer. Springer. Seminars in Immunotherapy. 2, 1979.

• 14) Bartelett, G. L. and Kreider, J. W.:Active, tumor-specific immunotherapy of LSTRA murine leukemia using irradiated cells and corynebacterium parvum. Proc., AACR and ASCO, 20:189, 1979.

• 15) Kim, K. S.:Tumor-specific immunity induced by somatic hybrids, II. Elicitation of enhanced immunity against the parent plasmacytoma. J. Immunol, 123:739, 1979.

• 16) Klein, G. and Klein, E.:Induction of tumor cell rejection in the low responsive YAC-lymphoma strain A host comhination by immunization with somatic cell hybrids. Eur. J. Cancer, 15:551, 1979.

• 17) Moriuchi, T. and Kobayashi, H.:Role of virus-associated antigen on xenogenized tumor cell surface in production of antibody against tumor-associated antigen. GANN Monogr. Cancer Res., 23:65, 1979.

• 18) Oikawa, T., Gotohda, E., Austin, F. C., Takeichi, N. and Boone, C. W.:Temperature-dependent alteration in immunogenicity of tumor-associated transplantation antigen monitored via paraformaldehyde fixation. Cancer Res., 39:3519, 1979.
  pubmed

• 19) Prager, M. D. and Gordon, W. C.:Immunoprophylaxis and therapy with lipid conjugated lymphoma cells. GANN Monogr. Cancer Res., 23:143, 1979.

• 20) Schapira, D. V., McCune, C. S. and Hensham, E. C.:Treatment of advanced renal cell carcinoma with specific immunotherapy of autologous tumor cells and C. parvum. Proc. AACR and ASCO, 20:348, 1979.

• 21) Skornick, Y. and Schinitzky, M.:Effective tumor immunization induce by cells of elevated membrane microviscosity. Abstract of Meeting on Immunological Aspects of Experimental and clinical cancer, Tel Avin, Israel. p. 153, 1979.

• 22) Yoshida, M. C.:Regression of Ehrlich ascites tumor in mice immunized by interspecific hybrid cells. Proc. Japan Acad., 55:238, 1979.

• 23) Zbar, B., Sukurmar, S. and Rapp, J.:Immunoprophylaxis of syngeneic murine sarcomas with BCG and tumor cells. Proc., AACR and ASCO, 20:55, 1979.

• 24) Kasai, M., Irie, R. F., Holmes, E. C. and Irie, K.:Increased cytotoxic sensitivity of mumps virus-infected melanoma cells to antibody from melanoma patients. Proc. AACR and ASCO, 21:220, 1980.

• 25) Mizushima, Y., Sendo, F., Takeichi, N., Hosokawa, M. and Kobayashi, H.:Enhancement of antitnmor transplantation resistance in rats by the antileukemia drug busulfan. Submitted to Cancer Res.

• 26) Mizushima, M., Sendo, F., Miyake, T. and Kobayashi, H.:Augmentation of specific cell-mediated immune responses to tumor cells in tumor bearing rats pretreated with the antileukemia drug busulfan. Submitted to J. Natl. Cancer Inst.

8. 腫瘍細胞の異物化

P.97 掲載の参考文献

• 1) Holterman, G. A. and Majde, J. A.:Rejection of skin and tumor grafts from mice chronically infected with lymphocytic choriomeningitis virus by non-infected syngeneic recipients. Nature, 223:624, 1969.

• 2) Kobayashi, H., Sendo, F., Kaji, H., Shirai, T., Saito, H., Takeichi, N., Hosokawa, M. and Kodama, T.:Modification in growth of transplantable rat tumors exposed to Friend virus. J. Natl. Cancer Inst., 42:413, 1969.

• 3) Bonmassar, E., Bonmassar, A., Vadlamudi S. and Goldin, A.:Immunological alteration of leukemic cells in vivo after treatment with an anti-tumor drug. Proc. Natl. Acad. Sci. USA, 66:1089, 1970.

• 4) Barbieri, D., Belehradek Jr. J. and Barski, G.:Decrease in tumor producing capacity of mouse cell lines following infection with mouse leukemia viruses. Int. J. Cancer., 7:364, 1971.
  pubmed

• 5) Basombrio, M. A.:Antigenic conversion of established tumors with the Moloney sarcoma virus. Proc. AACR and ASCO, 13:74, 1972.

• 6) Yamada, K. and Hatano, M.:Lowered transplantability of cultured tumor cells by persistent infection with paramyxovirus (HVJ) , Gann, 63:647, 1972.

• 7) Greenberger, J. S. and Aaronson, S. A.:In vivo inoculation of RNA C-type viruses inducing regression of experimental solid tumors. J. Natl. Canser Inst., 51:1935, 1973.

• 8) Boon, T. and Van Pel, A.:Teratocarcinoma cell variants rejected by syngenic mice:Protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc. Natl. Acad. Sci. USA, 75:1519, 1978.
  pubmed

• 9) Itaya, T., Moriuchi, T., Kodama, T. and Kobayashi, H.:Regression mechanism of xenogenized tumor cells in the view point of humoral immunity. Proc. Cancer Ass., 37:85, 1978.

• 10) Kodama, T., Kato, H., Gotohda, E., Kobayashi, H. and Sendo, F.:Regression of established tumors in rats by injection of diethylaminoethyl-dextran and Friend murine Leukemia virus., J. Natl. Cancer Inst., 61:403, 1978.
  pubmed

• 11) Kuzumaki, N., Fenyo, E. M., Klein, E. and Klein, G.:Protective effect of murine sarcoma virus (MSV) -superinfected mouse tumor cells against the outgrowth of the corresponding non-infected tumors. Transplantation., 26:304, 1978.

• 12) Kuzumaki, N., Fenyo, E. M., Giovanells B. C. and Klein, G.:Increased immunogenicity of low-antigenic rat tumors after superinfection with endogeneous murine C-type virus in nude mice., Int. J. Cancer, 21:62, 1978.

• 13) Takeichi, N, Austin, F. C., Oikawa, T. and Boone, C. W.:Augmented immunogenicity of tumor cell membranes produced by infection with influenza-virus, Cancer Res., 38:4580, 1978.
  pubmed

• 14) Kobayashi, H.:Viral xenogenization of intact tumor cells. Advances in Cancer Reserch. (Klein, G. and Weinhouse, S. ED.) , Academic Press (New York) :279-299, 1979.

• 15) Reed, L. M., Jones, C. L. and Holland, J.:Virus carrier state suppresses tumorgenicity of tumor cells in athymic (nude) mice., J. Gen. Virol., 42:609, 1979.

• 16) Takeyama, H., Kawashima, K., Yamada, K. and Ito, Y.:Induction of tumor resistence in mice by L1210 leukemia cells persistently infected with HVJ (Sendai virus) , Gann., 70:493-501, 1979.

• 17) Yamaguchi, H., Moriuchi, T., Kasai, M., Hosokawa, M., Kodama, T. and Kobayashi, H.:Relationship between immunogenicity and amounts of virus associated antigen in xenogenized tumor cells. Pro. Cancer Ass., 37:73, 1979.

• 18) Baldwin, R. W.:Personal communication.

9. 発癌と免疫監視

P.105 掲載の参考文献

• 1) Thomas, L.:Discussion. Cellular and Humoral Aspects of the Hypersensitive States:ed. H. S. Lawrence:p. 529. Cassell, London, 1959.

• 2) Miller, J. F. H. P., Grant, G. A. and Roe F. J. C.:Effect of thymectomy on the induction of skin tumour by 3, 4, benzopyrene. Nature, 199:920-922 1963.

• 3) Martinez, C.:Effect of early thymectomy on development of mammary tumor in mice. Nature, 203:1188, 1964.
  pubmed

• 4) Nishizuka, Y., Nakakuki, and Usui, M.:Enhancing effect of thymectomy on hepato tumorigenesis in Swiss mice following neonatl injection of 20-methylcholanthrene. Nature, 205:1236-1238, 1965.

• 5) Law., L. W., Ting, A. C. and Leckband, E.:The function of the thymus in tumour production by polyoma virus. ed. G. E. W. Wolstenholme and R. Porter:p. 214. Churchill, London, 1966.

• 6) Allison, A. C., Berman, L. D. and Levey, R. H.:Increased tumour induction by adenovirus type 12 in thymectomized mice and mice treated with anti-lymphocyte serum. Nature, 215:185-187, 1967.
  pubmed

• 7) Nomoto, K. and Takeya, K.:Immunologic properties of methylcholanthrene-induced sarcomas of neonatally thymectomized mice. J. Natl. Cancer Inst., 42:445-453, 1969.
  pubmed

• 8) Burnet, F. M:Immunological surveillance Pergamon Press. Oxford, 1970.

10. 発癌要因と免疫抑制

P.110 掲載の参考文献

• 1) 松本雄雄, 武市紀年 他:生体の免疫応答に影響する発癌関連因子. 腫瘍免疫学 (小林博, 橘武彦編) , 137-170, 朝倉書店, 1974.

• 2) 植竹久雄:ウイルス感染と免疫. 代謝, 16:23, 1979.

• 3) 松本雄雄:免疫抑制薬の作用機序. 新免疫学叢書 (眸柳武雄, 大高裕一, 松橋直編) , 4:72-89, 医学書院, 1979.

• 4) 松本雄雄:免疫抑制療法. 免疫治療学 (堀内淑彦, 松橋直, 橋本嘉幸, 矢田純一編) , 理工学社, 1980.

• 5) Baldwin, R. W.:Immunosuppression by chemical carcinogens. Adv. Cancer Res., 18:1-75, 1973.
  pubmed

• 6) Prehn, R. T.:Tumor progression and homeostasis. Adv. Cancer Res., 23:203-236, 1974.

• 7) Walburg, H. E. Jr.:Experimental radiation carcinogenesis. Adv. Radiation Biol., 4:209-254, 1974.

• 8) Stutman, O.:Immunodepression and malignancy. Adv. Cancer Res., 22:261-422, 1975.
  pubmed

11. 発癌と宿主要因

P.123 掲載の参考文献

• 1) 鈴木正勝, 水谷佐, 安井志郎:妊娠と急性白血病との合併に就て. 臨婦産. 8:707-717, 1954.

• 2) 田畑知敬:妊娠のマウス白血病におよぼす影響の免疫学的検討. 癌の免疫病理. 3:80-83, 1967.

• 3) 高杉遅:ステロイドホルモンによって誘起されるマウス膣上皮の不可逆性変化と腫瘍形式. 最新医学, 23:522-531, 1968.

• 4) 西塚泰章:内分泌環境と発癌. 臨床科学, 11:986-992, 1975.

• 5) 中森宏, 植田勝間, 追久男:細胞性免疫反応に及ぼすHCGの影響. 産婦進歩, 28:437, 1976.

• 6) 湯沢秀夫, 大野雅弘, 金沢浩二:各種抗原による免疫皮膚反応より見た正常及び異常妊・産・褥婦の免疫能. 産科と婦人科, 46 (11) :85-90, 1979.

• 7) 山内進, 塩塚幸彦, 小林一夫, 小沢敦:妊娠初期における母体の免疫反応とMasking factors. 臨床免疫, 12(12) :900-956, 1980.

• 8) Loeb, L., Burns, E. L., Suntzeff, V. and Moskop, M.:Carcinoma-like proliferations in vagina, cervix, and uterus of mouse treated with estrogenic hormones. Proc. Soc. Exp. Biol. Med., 35:320-322, 1936.

• 9) Furth, J.:Conditioned and autonomous neoplasms:A review. Cancer Res., 13:477-492, 1953.
  pubmed

• 10) Siegel, M. and Greenberg, M.:Incidence of Polyomyelitis in Pregnancy, Its Relation to Maternal Age, Parity and Geslational Period N. Engl. J. Med., 253:841-847, 1955.

• 11) Bern, H. A. and Nandi, S.:Recent studies of the hormonal influence in mouse mammary tumorigenesis. Prog. Exp. Tumor Res., 2:90-144, 1961.
  pubmed

• 12) Aoki, T., Teller, M. N. and Ralitaille, M. L.:Aging and cancerigenesis. II. Effect of age on phagocytic activity of the reticuloendotherial system and tumor growth. J. Natl. Cances Inst., 34:255-264, 1965.

• 13) Goullet, P. and Kaufmann, H.:Aging and antibody production in the rats. Experimentia, 21:46-47, 1965.

• 14) Gross, L.:Immunological defect in aged population and its relationship to cancer. Cancer, 18:201-204, 1965.
  pubmed

• 15) Hayflick, L.:The limited in vitro lifetime of human deploid cell strains. Exp. Cell Res., 37:614-636, 1965.

• 16) Peter, M. V.:Prognostic Factors in Breast Cancer, p. 65, 1967.

• 17) Teller, M. N. and Eilbert, M.:Aging and cancerigenesis. IV. Interrelationships among age, immune response and tumor incidence in several strains of mice. J. Natl. Cancer Inst., 32:231-239, 1967.

• 18) Huebner, R. J. and Todaro, G. J.:Oncogenes of RNA tumor viruses as determinants of cancer. Proc. Natl. Acad. Sci., 64:1087-1094, 1969.
  pubmed

• 19) Price, G. B. and Makinodan, T.:Immunologic deficiencies in senescence. I. Characterization of intrinsic deficiencies. J. Immunol., 108:403-412, 1972.
  pubmed

• 20) Murgita, R. A. and Tomasi, T. B., Jr.:Suppression of the immune response by α-fetoprotein. I. The effect of mouseα-fetoprotein on the primary and secondary antibody response. J. Exp. Med., 141:269-286, 1975.

• 21) Walters, C. S. and Claman, H. N.:Age related changed in cell mediated immunity of BALB/c mouse. J. Immunol., 115:1438-1443, 1975.
  pubmed

• 22) Burnet, F. M.:Aging, immunology, aging and cancer (W. H. Freeman and company) , p. 81-96, 1976.

• 23) Hirano, T. and Nordin, A.:Age-associated decline in the in vitro development of cytotoxic lymphocytes in NZB mice. J. Immunol., 117:1093-1098, 1976.
  pubmed

• 24) Kishimoto, S., Tsuyuguchi, I. and Yamamura, Y.:Immune responses in aged mice. Clin. Exp. Immunol., 5:525-530, 1976.

• 25) Smith, A.:The effects of age on the immune response to Type III pneumococcal polysaccharide (SIII) and bacterial lipopolysacharide (LPS) in BALB/c, SJL/J, and C 3H mice. J. Immunol., 116:469-474, 1976.

12. 腫瘍拒絶と細胞性免疫

P.133 掲載の参考文献

• 1) 仙道富士郎:Natural Killer. 免疫'78 (山村雄一, 多田富雄監編) , 55-63, 中山書店, 1978.

• 2) 多田富雄:免疫応答における自己認識, 免疫'78 (山村雄一, 多田富雄監編) , 15-22, 中山書店, 1978.

• 3) 小室勝利ら:担癌マウスに出現するADCC活性を有するT細胞の性状. 第38回日本癌学会記事, 1979.

• 4) Mackaness, G. B.:The immunological basis of acquired cellular resistance. J. Exp. Med., 120:105-120, 1964.
  pubmed

• 5) Evans, R. and Alexander, P.:Cooperation of immune lymphoid cells with macrophage in tumor immunity. Nature, 228:620-624, 1970.
  pubmed

• 6) Zbar, B. et al.:Tumor-Graft rejection in syngeneic guinea pig:Evidence for a two-step mechanism. J. Natl. Cancer Inst., 44:473-481, 1970.
  pubmed

• 7) Greenberg, A. H. et al.:Characterization of the antibody-dependent cytotoxic cell. A non-phagocytic monocyte? Clin. Exp. Immunol., 15:251-259, 1973.
  pubmed

• 8) Rosenthal, A. S. and Shevach, E. M.:Function of macrophages in antigen recognition by guinea pig T lymphocytes. J. Exp. Med., 138:1194-1212, 1973.
  pubmed

• 9) Kobayashi, H. et al.:Reduced transplantability of syngeneic tumors in rats immunized with allogeneic tumors. Int. J. Cancer, 13:522-529, 1974.
  pubmed

• 10) Stutman, O.:Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science, 183:534-536, 1974.
  pubmed

• 11) Krahenbuhe, J. L. and Remington, J. S.:The role of activated macrophages in specific and nonspecific cytostasis of tumor cells. J. Immunol., 113:507-516, 1974

• 12) Cantor, H. and Boyse, E. A.:Functional subclases of T lymphocytes bearing differently antigens. J. Exp. Med., 141:1376-1389, 1975.

• 13) Greenberg, A. H. et al:Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. II. The mouse nonadherent K cell. Eur. J. Immunol., 5:474-480, 1975.

• 14) Kiessling, R. et al.:"Natural"killer cells in the mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol., 5:112-117, 1975.
  pubmed

• 15) Lamon, E. W. et al.:Antibody dependent lyphocyte cytoxicity in the murine sarcoma virus system:Activity of IgM and antigen (S) . J. Immunol, 114:1171-1176, 1975.

• 16) Zinkernagel, R. M. and Doherty, P. C.:H-2 compatibility requirement for T-cell-mediated lysis of target cells infected with lymphocitic choriomeningitis virus. J. Exp. Med., 141:1427-1436, 1975.

• 17) Nelson, D. L. et al.:The effector cell in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity. J. Immunol., 117:1472-1481, 1976.
  pubmed

• 18) Gomard, E. et al.:H-2 region product as determinant if immune cytolysis of syngeneic tumor cells by anti-MSV T lymphocytes. Nature, 260:707-709, 1976.
  pubmed

• 19) Wahlin, B. et al.:Analysis by a plaque assay of IgG-or IgM-Dependent cytolytic lymphocytes in human blood. J. Exp. Med., 144:1375-1385. 1977.

• 20) Ting, C. C. and Law, L. W.:Studies of H-2 Restriction in cell-mediated cytotoxicity and transplantation immunity to leukemia-associated antigens. J. Immunol., 118:1259-1270, 1977.
  pubmed

• 21) Aya, T. et al:0ncogenesis and herpes viruses III/part 2 pp. 711, de The, G et al. (ed.) , Lyon, 1978.

• 22) Cudckowicz, G. et al. (ed.) :Natural resistance systems against forein cells, tumors and microbes. Academic Press, N. Y., 1978.

• 23) Droller, M. T. et al.:Enhancement of natural and antibody-dependent lymphocyte cytotoxicity by drugs which inhibit prostaglandin production by tumor target cells. Cell. Immunol., 39:154-164, 1978.

• 24) Landolfo, S. et al.:Macrophage-lymphocyte interaction in migration inhibition factor (MIF) production against soluble or cellular tumor associated antigens. J. Immunol., 121(2) :695-701, 1978.
  pubmed

• 25) Milgrom, H. et al.:Lysis of antibody-coated human red cells by peripheral blood mononuclear cells. Altered effector cell profile after treatment of target cells with enzymes. Cell. Immunol., 39:178-193, 1978.
  pubmed

• 26) Nakayama, M. et al.:Nonspecific Inhibition of tumor growth by allosensitized lymphocytes. J. Immunol., 120:619-623, 1978.
  pubmed

• 27) Pearson, G. R. et al.:Antibody-Dependent Cellular cytotoxicity against Epstein-barr virus-associated antigens in African patients with Nasopharyngel carcinoma. J. Cancer, 22:120-125, 1978.

13. 腫瘍拒絶と液性抗体

P.151 掲載の参考文献

• 1) Weil, E. und Braun, H.:Uber Antikorper bei Tumoren. Wien. Klin. Wschr. 21:650-652, 1908.

• 2) Ehrlich, P.:Ned. Tijdscr. Geneesk. 5:1, 1909.

• 3) Prehn, R. T. and Lappe, M. A.:Transplant. Rev. 7, 26:1971.
  pubmed

• 4) Kaliss, N:Immunological enhancement of tumor homografts in mice. A review. Cancer Res., 18:992-1003, 1958.
  pubmed

• 5) Ngu, V. A.:Host defence to Burkitt tumour. Brit. Med. J., 1:345-347, 1967.
  pubmed

• 6) Hellstrom, I. and Hellstrom, K. E.:Studies on cellular immunity and its serum-mediated inhibition in Moloney-virus-induced mouse sarcomas. Int. J. Cancer, 4:587-600, 1969.
  pubmed

• 7) Burnet, F. M.:Immunological surveillance in neoplasia. Transplant Rev. 7:3-25, 1971.
  pubmed

• 8) Kassel, R. L., Old, L. J., Carswell, E. A., Fiore, N. C. and Hardy, W. D.:Serum-mediated leukemia cell destruction in AKR mice, Role of complement in the phenomenon. J. Exp. Med., 138:925-938, 1973.

• 9) Irie, R. F., Irie, K. and Morton, D. L.:Natural antibody in human serum to a neoantigen in human cultured cells grown in fetal bovine serum. J. Natl. Cancer Inst., 52:1051-1058, 1974.
  pubmed

• 10) Martin, W. J. and Martin, S. E.:Naturally occurring cytotoxic anti-tumour antibidies in sera of congenitally athymic (nude) mice. Nature, 249:564-565, 1974.

• 11) Rubinstein, P., Decary, F. and Streun, E. D.:Ouantitative studies on tumor enhancement in mice. J. Exp. Med., :591-596, 1974.

• 12) Rygaad, J., Povlsen, C. O.:Is immunological surveillance not a cell-mediated immune function?. Transplantation, 17:135-136, 1974.
  pubmed

• 13) Menard, S., Colnaghi, M. I. and Porta, G. D.:Natural antitumor serum reactivity in BALB/c mice. I. charactrization and inheritance with tumor growth. Int. J. Cancer. 19:267-274, 1977.

14. 腫瘍免疫と組織適合抗原遺伝子

P.161 掲載の参考文献

• 1) 本庶 佑:免疫グロブリン遺伝子の再構成と発現免疫'78. 山村雄一, 多田富雄監編, 代謝, 15:75-82, 1978.

• 2) 橘 武彦:癌細胞特異抗原の免疫化学的研究. p. 58. 昭和54年度「がん」特別研究研究報告集録

• 3) Old, L. J., Boyse. E. A. and Stockert, E.:Antigenic properties of experimental leukemias. I. Serological studies in vitro with spontanous and radiation-induced leukemias. J. Natl. Cancer Inst., 37:977-986, 1963.

• 4) Reif, A. E. and Allen, J. M. V.:Specificity of isoantisera against leukemic and thymic lymphocytes. Nature (London) , 200:1332-1333, 1963.

• 5) Boyse, E. A., Stockert, E. and Old, L. J.:Modification of the antigenic structure of the cell membrane by TL antibody. Proc. Natl. Acad. Sci., USA, 58:954-957, 1967.
  pubmed

• 6) Haywood, G. R., and Mckhann, C. F.:Antigenic specificities on murine sarcoma cells. Reciprocal relationship between normal transplantation antigens (H-2) and tumor-spefic immunogenicity. J. Exp. Med., 133:1171-1187, 1971.

• 7) Itakura, K., Hutton, J. J., Boyse, E. A. and Old, L. J.:Linkage groups of θ and Ly-A loci. Nature New Biol., 230:126, 1971.

• 8) Jerne, N. K.:The somatic generation of immune recognition. Eur. J. Immunol., 1:1-9, 1971.
  pubmed

• 9) Itakura, K., Hutton, J. J., Boyse, E. A. and Old, L. J.:Genetic linkage relationships of loci specifying defferentiation alloantigens in the mouse. Transplantation, 13:239-243, 1972.

• 10) Bodmer, W. F.:A new genetic model for allelism at histocompability and other complex loci:polymorphism for control of gene expression. Transpl. Proc., 5:1471-1475, 1973.

• 11) Demant, P., Capkova, J., Hinzova, A. and Voracova, B.:The role of the histocompatibility-2-linked Ss-Slp region in the control of mouse complement. Proc., Natl., Acad., Sci., USA, 70:863-864, 1973.
  pubmed

• 12) Martin, W. J., Esber, E., Cotton, W. G. and Rice, J. M.:Depression of alloantigens in malignancy. Evidence for tumor susceptibility alloantigens and for possible self-reactivity of lymphoid cells active in the microcytotoxicity assay. Brit. J. Cancer, 28:48-61, 1973.

• 13) Snell, G. D., Cherry, M., McKenzie, I. F. C. and Bailey, D., W.:Ly-4, a new locus determining a lymphocyte cell-surface alloantigen in mice. Proc. Natl. Acad. Sci., USA, 70:1108-1111, 1973.

• 14) Artzt, K., Bennett, D. and Jacob, F.:Primitive teratocarcinoma cells express a differentiation antigen specified by a gene at T-locus in the mouse. Proc. Natl. Acad., Sci., USA, 71:811-814, 1974.
  pubmed

• 15) Wainberg, M. A., Markson, Y., Weiss, D. W. and Doljanski, F.:Cellular immunity against Rous sarcomas of chickens. Preferential reactivity against autochthonous target cells as determined by lymphocyte adherance and cytotoxicity tests in vitro. Proc. Natl. Acad., Sci., USA, 71:3565-3569, 1974.
  pubmed

• 16) Bevan, M. J.:Interaction antigens detected by cytotoxic T cells with the major histocompatibility complex as modifier. Nature (London) , 256:419-421, 1975.
  pubmed

• 17) Blanden, R. V., Doherty, P. C., Dunlop, M. B. C., Gardner, I. D. and Zinkernagel, R. M.:Genes required for cytotoxicity against virus-infected target cells in K and D regions of H-2 complex. Nature (London) , 254:269-270, 1975.

• 18) Canter, H. and Boyse, E. A.:Functional subclass of T lymphocyte bearing different Ly antigens.:II. Cooperation between subclass of Ly+ cells in the generation of killer activity. J. Exp. Med., 141:1390-1399, 1975.

• 19) David, C. S., Stimpfling, J. H. and Shreffler. D. C.:Identification of specificity H-2. 7 as an erythrocyte antigen:Control by an independent locus, H-2G between the S and D regions. Immunogenetics, 2:131-139, 1975.

• 20) Gardner, I. D., Bowern, N. A. and Blanden, R. V.:Cell-mediated cytotoxicity against ectromelia virus-infected target cells. III. Role of the H-2 gene complex. Eur. J. Immunol., 5:122-127, 1975.

• 21) Germain, R. N., Dorb, M. E. and Benacerraf, B.:Inhibition of T-lymphocytemediated tumor-specific lysis by alloantisera directed against the H-2 serological specificities of the tumor. J. Exp. Med., 142:1023-1028, 1975.

• 22) Gordon, R. D., Simpson, E. and Samelson, L. E.:In vitro cell-mediated immune responses to the male specific (H-Y) antigen in mice. J. Exp. Med., 142:1108-1120, 1975.

• 23) Invernizzi, G. and Parimiani, G.:Tumor-associated transplantation antigens of chemically induced sarcomata cross reacting with allogeneic histocompatibility antigens. Nature (London) , 254:713-714, 1975.

• 24) Koszinowski, U. and Thomssen, R.:Target cell-dependent T cell-mediated lysis of vaccinia virus-infected cells. Eur. J. Immunol., 5:245-251, 1975.
  pubmed

• 25) Schrader, J. W., Cunningham, B. A. and Edelman, G. M.:Functional interactions of viral and histocompatibility antigens at tumor cell surfaces. Proc. Natl. Acad. Sci., USA, 72:5065-5070, 1975.

• 26) Shearer, G. M., Rehn, T. G. and Garbarino, C. A.:Cell-mediated lympholysis of trinitrophenyl-modified cell surface components controlled by the H-2K and H-2D serological regions of murine major histocompatibility complex. J. Exp. Med., 141:1348-1364, 1975.

• 27) Binz, H., Wigzell, H. and Bazin, H.:T cell idiotype are linked to immunoglobulin heavy chain genes. Nature (London) , 264:639-642, 1976.
  pubmed

• 28) Chesebro, B. and Wehrly, K.:Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity, J. Exp. Med., 143:85-99, 1976.
  pubmed

• 29) Forni, G., Shevach, E. M. and Green, I.:Mutant lines of guinea pig L2C leukemia. I. Deletion of Ia alloantigen is associated with a loss in immunogenicity of tumorassociated transplantation antigens. J. Exp. Med., 143:1067-1081, 1976.
  pubmed

• 30) Gomard, E., Duprez, V., Henin, Y. and Levy, J. P.:H-2 region product as determinant in immune cytolysis of syngeneic tumor cells by anti-MSV T lymphocytes. Nature (London) , 260:707-709, 1976.

• 31) Schmitt-Verhulst, A. M., Sachs, D. H. and Shearer, G. M.:Cell-mediated lympholysis of trinitrophenyl-modified autologous lymphocytes. Confirmation of genetic control of response to trinitrophenyl-modified H-2 antigens by the. use of anti-H-2 and anti-Ia antibodies. J. Exp. Med., 143:211-217, 1976.
  pubmed

• 32) Stanton, T. H. and Boyse, E. A.:A new serologically defined locus Qa-1 in the Tla-region of the mouse. Immunogenetics, 3:525-531, 1976.

• 33) Thompson, D. M. P., Gold, P., Freedman, S. O. and Shuster, J.:The isolation and characterization of tumor specific antigens of rodent and human tumors. Cancer Res., 36:3518-3525, 1976.

• 34) Trinchieri, G., Aden, D. P. and Knowles, B. B.:Cell-mediated cytotoxicity to SV40-specific tumor-associated antigens. Nature (London) , 261:312-314, 1976.
  pubmed

• 35) Bach, F. H., Grillot-Courvalin, C., Kuperman, O. J., Sollinger, H. W., Hayes, C., Sonder, P. M., Alter, B. J. and Bach, M:Antigenic reqirement for triggering of cytotoxic T lymphocyte. Immunol. Rev., 35:76-96, 1977.

• 36) Holden, H. T. and Herberman R. B.:Cytotoxicity against tumor-associated antigen not H-2 restricted. Nature (London) , 268:250-252, 1977.

• 37) Klein, G.:Tumor-associated antigensin H-2 hemizygous isoantigenic variants on a somatic cell hybrid, derived from the fusion of a 3-methylcholanthrene-induced sarcoma and a mammary carcinoma. J. Natl. Cancer, Inst., 58:383-386, 1977.

• 38) Ting. C. C. and Law, L. W.:Studies of H-2 restriction in cell-mediated cytotoxicity and transplantation immunity to leukemia-associated antigens. J. Immunol., 118:1259-1264, 1977.
  pubmed

• 39) Gipson, T. G, Imamura, M., Conliffe, M. A. and Martin, W. J.:Lung tumor associated depressed alloantigen coded for by the K region of the H-2 major histocompatibility complex. J. Exp. Med., 147:1363-1373, 1978.

• 40) Natori, T., Law, L. W. and Apella, E.:Immunochemical evidence of a tumor-specific surface antigen obtained by detergent solubilization of the membrane of chemically induced sarcoma, Meth-A. Cancer, Res., 38:359-364, 1978.

• 41) Tokuhisa, T., Taniguchi, M., Okumura, K. and Tada, T.:An antigen-specific I-region gene product which augments the antibody response. J. Immunol., 120:414-421, 1978.
  pubmed

• 42) Curry, R. A., Quaranta, V., Wilson, B. S., McCabe, R. P., Natali, P. G., Pellegrino, M. A. and Ferrone, S.:Expression of HLA antigens on cultured human melanoma cells:Lack of association with melanoma-associated antigens. In Current Trends in Tumor Immunology. ed, by Ferrone, S., Gorini, S., Herberman, R. B. and Reisfeld, R. A. Garland STPM press, New York and London, p. 347-366, 1979.

15. 腫瘍免疫とIr遺伝子

P.171 掲載の参考文献

• 1) Heston, W. E.:Genetic analysis of susceptibility to induced pulmonary tumors in mice. J. Natl Cancer Inst., 3:69-78, 1942.

• 2) Strong, L. C.:Genetic analysis of the induction of tumors by methylcholanthrene. IX. Induced and spontanous adenocarcinomas of the stomach in mice. J. Natl. Cancer Inst., 5:339-362, 1945.

• 3) Levine, B. B., Ojeda, A. and Benacerraf, B.:Studies on artificial antigens. III. The genetic control of the immune response to hapten poly-L-lysine conjugates in guinea pigs. J. Exp. Med., 118:953-957, 19630.

• 4) McDevitt, H. O. and Sela, M.:Genetic control of the antibody response. I. Demonstration of determinant-specific difference in response to sythetic poly-peptide antigens in two strain of inbred mice. J. Exp. Med., 122:517-531, 1965.

• 5) Old, L. J., Boyse, E. A. and Stockert, E.:The G (Gross) leukemia-antigen. Cancer Res., 25:813-819, 1965.

• 6) Aoki, T., Boyse, E. A. and Old, L. J.:Occurrence of natural antibody to the G (Gross) leukemia antigen in mice. Cancer Res., 26:1415-1419, 1966.

• 7) Lilly, F.:The inheritance of susceptibility to the Gross leukemia virus in mice. Genetics, 53:529-539, 1966.

• 8) Mc Coy, J. L., Fefer, A. and Glynn, J. P.:Comparative studies on the induction of transplantation resistance in BALB/c and C57BL/6 mice in three murine leukemia systems. Cancer Res., 27:1743-1748, 1967.

• 9) Chihara, G., Maeda, Y., Hamuro, J., Sasaki, T. and Fukuoka. F.:Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk) Sing. Nature (London) , 222:687-688, 1969.
  pubmed

• 10) Odaka, T.:Inheritance of susceptibility to. Friend mouse leukemia virus. VII. Establishment of a resistant strain. Int. J. Cancer, 6:18-23, 1970.
  pubmed

• 11) Lilly, F.:Fv-2:Identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice, J. Natl. Cancer Inst., 45:163-169, 1970.
  pubmed

• 12) Lilly, F.:The influence of H-2 type on Gross virus leukemogenesis in mice. Transpl. Proc., 3:1239-1241, 1971.

• 13) Cudkowicz, G, Rossi, G. B., Haddad, J. R. and Friend, C.:Hybrid resistance to parental DBA/2 grafts:Independence from the H-2 locus. II. Studies with Friend virus-induced leukemia cells. J. Natl. Cancer Inst., 48:997-1003, 1972.

• 14) Hanna, M. G., Tennant, R. W., Yuhas, J. M., Clapp, N. K., Batzing, B. L. and Snodgrass, M. J.:Autogenous immunity to endogenous RNA tumor virus antigens in mice with a low natural incidence of lymphoma. Cancer Res., 32:2226-2234, 1972.
  pubmed

• 15) Kersey, J. H., Spector, B. D. and Good, R. A.:Primary immunodeficiency diseases and cancer:The immunodeficiency-cancer registry. Int. J. Cancer, 12:333-347, 1973.

• 16) Kouri, R. E., Ratrie, H. and Whitmire, C. E.:Evidence of a genetic relationship between susceptibility to 3-methylcholanthrene-induced subcutaneous tumors and inducibility of arylhydrocarbon hydroxylase. J. Natl. Cancer Inst., 51:197-200, 1973.

• 17) Rowe, W. P. and Sato, H.:Genetic mapping of the Fv-1 locus of the mouse. Science. 180:640-641, 1973.
  pubmed

• 18) Sato, H., Boyse, E. A., Aoki, T., Iritani, C. and Old, L. J.:Leukemia-associated transplantation antigens related to murine leukemia virus. The X. 1 system:Immune response controlled by a locus linked to H-2. J Exp. Med., 138:593-606, 1973.

• 19) Dausset, J., Degos, L. and Hors, J.:A review:The association of HL-A antigens with diseases. Clin. Immunol. Immunopathol., 3:127-149, 1974.
  pubmed

• 20) Maeda, Y. Y., Chihara, G. and Ishimura, K.:Unique increase of serum protein and action of antitumour polysaccharides. Nature (London) , 252:250-251, 1974.
  pubmed

• 21) Dorf, M. E. and Benacerraf, B.:Complementation of H-2 linked Ir genes in the mouse. Proc. Natl. Acad. Sci., USA, 72:3671-3675, 1975.
  pubmed

• 22) Herberman, R. B., Nunn, M. E. and Larrin, D. H.:Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int. J. Cancer, 16:216-239, 1975.

• 23) Katz, D. H. and Armerding, D.:Evidence for the control of lymphocyte interactions by gene products of the I region of the H-2 complex. In Immune Recognition. ed. by Rosenthal, A. S. Acad. Press Inc., New York, San Francisco and London, p. 727-753, 1975.

• 24) Kiesling, R., Petranyi, G, Klein G. and Wigzell, H.:Genetic variation of in vitro cytotoxic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line. Int. J. Cancer, 15:933-940, 1975.

• 25) Kiessling, R., Klein, E. and Wigzell, H.:"Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol., 5:112-121, 1975.
  pubmed

• 26) Sendo, F., Aoki, T., Boyse, E. A. and Buofo, C. K.:Natural occurrence of lymphocytes showing cytotoxic activity to BALB/c radiation induced leukemia RL♂1 cells. J. Natl. Cancer Inst., 55:603-609, 1975.

• 27) Taylor, A. M. R. Haruden, D. G, Arlett, C. F., Harcourt, S. A. Lehmann, A. R. Stevens, S. Bridges, B. A.:Ataxia telangiectasia:A human mutation with abnormal radiation sensitivity. Nature 258, 427-429, 1975.

• 28) Williams, R. M., Dorf, M. E. and Benacerraf, B.:H-2 linked genetic control of resistance to histocompatible tumors. Cancer Rer., 35:1586-1590, 1975.

• 29) Okumura, K., Herzenberg, L. A., Murphy, O. B., McDevitt, H. O. and Herzenberg L. A.:Selective expression of H-2 (I-region) loci controlling determinants on hapten and suppressor T lymphocytes. J. Exp. Med., 144:685-692, 1976.

• 30) Petrani, G. G., Kiesling, R., Povey, S., Klein, G., Herzenberg, L. and Wigzell, H.:The genetic control of natural killer cell activity and its association with in vivo resistance against a Moloney lymphoma isograft. Immunogenetics, 3:15-28, 1976.

• 31) Green, M. I., Dorf, M. E., Pierres, M. and Benacerraf. B.:Reduction of syngeneic tumor growth by an anti-I-J allo antiserum. proc. Natl., Acad., Sci., USA, 74:5118-5121, 1977.

• 32) Klein, G., Klein, G. O., Karre, K. and Kiesling. R.:"Hybrid resistance" against parental tumors.:One or several genetic patterns? Immunogenetics, 7:391-404, 1978.
  pubmed

• 33) Ruco, L. P., Meltzer, M. S. and Rosenstreich, D. L.:macrophage activation for tumor cytotoxicity:Control of macrophage tumoricidal capacity by the LPS gene. J. Immunol., 121:543-548, 1978.

• 34) Sasazuki, T., Kohno, Y., Iwamoto, I., Tanimura, M. and Naito, S.:Association between an HLA haplotype and low responsiveness to tetanus toxoid in man. Nature (London) , 272:359-361, 1978.

• 35) Roder, J. and Duwe, A.:The beige mutation in the mouse selectively impairs natural killer cell function. Nature (London) , 278:451-453, 1979.
  pubmed

• 36) Walker, M. C. and Phillips-Qualiata, J. M.:Hybrid resistance to BALB/c plasmacytomas. I. Resistance to MPC-11 controled by a locus not linked to H-2. J. Immunol., 122:1535-1543, 1979.

16. 腫瘍免疫と細胞工学

P.182 掲載の参考文献

• 1) Barski, G. and Cornefert, F.:Characteristics of "hybrid"-type clonal cell lines obtained from mix cultures in vitro. J. Natl. Cancer Inst., 28:801-821, 1962.

• 2) Okada, Y.:Analysis of giant polynuclear cell formation caused by HVJ virus from Ehrlich's ascites tumor cells. J. Microscopic observation of giant polynuclear cell formation. Exp. cell Res., 26:98-107, 1962.

• 3) Gershon, D. and Sachs, L.:Properties of a somatic hybrid between mouse cells with different genotypes. Nature (London) , 198:912-913, 1963.
  pubmed

• 4) Littlefield, J. W.:Selection of hybrids from mating of fibroblasts in vitro and their presumed recombinants. Science, 145:709-710, 1964.
  pubmed

• 5) Weiss, M. C. and Green, H.:Human-mouse hybrid cell lines containing partial complements of human chromosomes and functioning human genes. Proc. Natl. Acad. Sci., 58:1104-1111, 1967.
  pubmed

• 6) Harris, H., Miller, O. J., Klein, G., Worst, P. and Tachibana, T.:Suppression of malignancy by cell fusion. Nature (London) , 223:363-368, 1969.
  pubmed

• 7) Nabholz, M., Miggiano, V. and Bodmer, W.:Genetic analysis with human mouse somatic cell hybrids. Nature (London) , 223:358-363, 1969.
  pubmed

• 8) Klein, G., Gars, U., Harris, H.:Isoantigen expression ill hybrid mouse cells. Exp. Cell Res., 62:149-160, 1970.

• 9) Caspersson, T., Lonmakka, G. and Zech, L.:The 24 fluorescence patterns of the human metaphase chromosomes-distinguishing characters and variability, Hereditas, 67:89-102, 1971.

• 10) Coffino, P., Knowles, B., Nathenson, S. G. and Schaff, M. D.:Suppression of immunoglobulin synthesis by cell hybridization. Nature New Biol. 231:87-90, 1971.

• 11) Hitotsumachi, S., Rabinowitz, Z., and Sachs, L.:Chromosomal control of reversion in transformed cells. Nature (London) , 231:511-514, 1971.
  pubmed

• 12) Miller, O. J., Allderdice, P. W., Miller, D. A., Breg, W. R. and Migeon, B. R.:Human thymidine kinase gene locus:Assignment to chromosome 17 in a hybrid of man and mouse cells. Science, 173:244-245:1971.

• 13) Mohit, B. and Fan, K.:Hybrid cell line from a cloned immunoglobulin-producing mouse myeloma and a nonproducing mouse lymphoma. Science, 171:75-77, 1971.

• 14) Harris, H.:Cell fusion and analysis of malignancy. J. Natl. Cancer Inst., 48:851-864. 1972.

• 15) Cotton, R. G. H. and Milstein, C.:Fusion of two immunoglobulin producing myeloma cells. Nature (London) , 244:42-43, 1973.

• 16) Jami, J. and Ritz, E.:Expression of tumor-specific antigens in mouse somatic cell hybrids. Cancer Res., 33:2524-2528, 1973.
  pubmed

• 17) Parkman, R. and Merler, E.:Thymus-dependent functions of mouse thymocyte-fibroblast hybrid cells. Nature New. Biol., 245:14-16, 1973.
  pubmed

• 18) Croce, C. M. and Koprowski, H.:Somatic cell hybrids between mouse peritoneal macrophages and SV40-transformed human cells. I. Positive control of the transformed phenotype by the human chromosome 7 carring the SV40 genome. J. Exp. Med., 140:1221-1229, 1974.

• 19) Darlington, G., Bernhard, H. P. and Ruddle, F. H.:Human serum albumin phenotype activation in mouse hepatomahuman leukocyte cell hybrids. Science, 185:859-862, 1974.

• 20) Kennett, R. H., Hampshire, B., Bengtsson, B. and Bodmer, W. F.:Expression and segregation of HL-A antigens in D98/AH-2 by lymphocyte and fibroblast hybrids. Tissue Antigens, 6:80-92, 1975.
  pubmed

• 21) Kohler, G. and Milstein, C.:Continuous cultures of fuzed cells secreting antibody of predefined specificity. Nature (London) , 256:495-497, 1975.

• 22) Dennert, G., and Raschke, W.:Continuously proliferating allospecific T cells, lifespan and antigen receptors. Eur. J. immunol., 7:352-359, 1977.
  pubmed

• 23) Fellous, M., Kamoun, M., Wiels, J., Dausset, J., Clements, G., Zeuthen, J., Klein, G.:Induction of HLA expression in Daudi cells after cell fusion. Immunogenetics, 5:423-436, 1977.

• 24) Fournier, R. E. K. and Ruddle, F.:Microcell-mediated transfer of murine chromosomes into mouse, chinese hamster and human somatic cells. Proc. Natl. Acad. Sci., 74:319-323, 1977.

• 25) Francke, U. and Pellegrino, M. A.:Assignment of the major histocompatibility complex to a region of the short arm of human chromosome 6. Proc. Natl. Acad. Sci., 74:1147-1151, 1977.
  pubmed

• 26) Klein, G.:Tumor-associated antigens in H-2 hemizygous isoantigenic variants of a somatic cell hybrid, derived from the fusion of a 3-methylcholanthraneinduced sarcoma and a mammary carcinoma. J. Natl Cancer Inst., 58:383-386, 1977

• 27) Shay, J. W.:Selection of reconstituted cells from karyoplast fused to chloramphenicol resistant cytoplasts. Proc. Natl. Acad, Sci., 74:2461-2464, 1977.
  pubmed

• 28) Hammerling, G. J., Lemke, H, Hammerling, U., Hohmann, C., Wallich, R. and Rajewsky, K.:Monoclonal antibodies against murine cell surface antigens:Anti-H-2, anti-Ia and anti-T cell antibodies. Curr. Top. Microbiol. Immunol., 81:100-106, 1978.
  pubmed

• 29) Hyman, R. and Stallings, V.:Evidence for a gene extinguishing cell-surface expression of the Thy-1 antigen. Immunogenetics, 6:447-458, 1978.

• 30) Knowles, B. B., Aden, D. P. and Solter, D.:Monoclonal antibody detecting a stage specific embryonic antigen (SSEA-1) on preimplantation mouse embryos and teratocarcinoma cells. Curr. Top. Microbiol. Immunol., 81:51-53, 1978.
  pubmed

• 31) Koprowski, H., Gerhard, W, Wiktor, T., Martinis, J., Shander, M. and Croce, C. M.:Anti-viral and anti-tumor anibodies produced by somatic cell hybrids. Curr. Top. Microbiol. Immunol., 81:8-19, 1978.

• 32) Koprowski, H., Steplewski, Z., Herlyn, D. and Herlyn, M.:Study of antibodies against human melanoma produced by somatic cell hybrids. Proc. Natl. Acad. Sci., 75:3405-3409, 1978.
  pubmed

• 33) Parham, P. and Bodmer, W. F.:Monoclonal antibody to a human major histocompatibility alloantigen, HLA-A2. Nature (London) , 276:397-398, 1978.

• 34) Lostrom, M. E., Stone, M. R., Tam, M., Nealburnette, W., Pinter, A. and Nowinski, R. C.:Monoclonal antibodies against murine leukemia virus:Identification of six antigenic determinant on P15 (E) and GP70 envelope protein. Virology, 98:336-350, 1979.

• 35) Shin. C., Shilo, B. Z., Goldfarb, M. P., Dannenberg, A. and Weinberg, R. A.:Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc. Natl. Acad. Sci., 76:5714-5718, 1979.

• 36) Taniguchi, M., Saito, T. and Tada, T.:Antigen-specific suppressive factor produced by transplantable I-J bearing T-cell hybridoma. Nature (London) , 278:555-558, 1979.

• 37) Yeh, M. Y., Hellstrom, I., Brown, J. P., Warner, G. A., Hansen, J. A. and Hellstrom, K. E.:Cell surface antigens of human melanoma identified by monoclonal antibody. Proc. Natl. Acad. Sci., 76:2927-2931, 1979.
  pubmed

• 38) Nador, L. M., Stashenko, P., Hardy, R. and Schlossman, S. T.:A monoclonal antibody defining a lymphoma-associated antigen in man. J. Immunol., 125:570-577, 1980.

• 39) Takatsu, K., Tanaka, K., Tominaga, A., Kumahara, Y. and Hamaoka, T.:Antigen-induced T cell-replacing factor (TRF) . III. Establishment of T cell hybrid clone continuously producing TRF and functional analysis of released TRF. J. Immunol., 125:2367-2373, 1980.

• 40) Uotila, M., Engvall, E. and Ruoslahti, E.:Monoclonal antibodies to alphafetoprotein. Molecular Immunol., 17:791-794, 1980.

• 41) Nable, G., Fresno, M., Chessman, A. and Cantor, H.:Use of cloned populations of mouse lymphocytes to analyze callular differentiation. Cell, 23:19-28, 1981.

• 42) Saxton, R. E., Burk, M. W., Irie, R. F. and Morton, D. L.:Melanoma cell surface antigens:Isolation by monoclonal antibody affinity chromatography. AACR proc. 22:299, 1981.

17. 癌細胞の免疫学的逃避

P.195 掲載の参考文献

• 1) 小玉孝郎, 武市紀年:各系ラットフレンド腫瘍細胞表面の酸性ムコ多糖類とくにシアロムチンの電子顕微鏡的研究. 最新医学, 27:1194-1197, 1972.

• 2) Kaliss, N. and Molomut, N.:The effect of prior injections of tissue antiserums on the survival of cancer homografts in mice. Cancer Res., 12:110-112, 1952.

• 3) Kaliss, N.:Immunological enhancement of tumor homografts in mice. A review. Cancer Res., 18:992-1003, 1958.
  pubmed

• 4) Moller, G.:Effect of tumor growth in syngeneic recipients of antibodies against tumor-specific antigens in methylcholanthreneinduced mouse sarcomas. Nature, 204:846-848, 1964.
  pubmed

• 5) Bubenik, J. and Koldovsky, P.:Factors influencing the induction of enhancement and resistance to methylcholanthrene-induced tumors in a syngeneic system. Folia Biol. (Praha) , 11:258-265, 1965.

• 6) Chard, T., French, M. E. and Batchelor, J. R.:Enhancement of the C57BL leukemia EL4 by Fab fiegments of isoantibody. Transplantation, 5:1266-1272, 1968.

• 7) Currie, G. A., Van Doorninck, W. and Bagshawe, K. D.:Effect of neuraminidase on the immunogenicity of early mouse trophoblast. Nature (Lond.) , 219:191-192, 1968.
  pubmed

• 8) Hellstrom, I. and Hellstrom, K. E.:Studies on cellular immunity and its serum-mediated inhibition in Moloney-virus-induced mouse sarcomas Int. J. Cancer, 4:587-600, 1969.
  pubmed

• 9) Hellstrom, K. E. and Hellstrom, I.:Immunological enhancement as studied by cell culture techniques. Annu. Rev. Microbiol., 24:373-396, 1970.
  pubmed

• 10) Kojima K., Takeichi, N., Kobayashi, H. and Maekawa, A.:Electrokinetic charge of transplantable Friend virus-induced tumors in rats. Nagoya Med. J., 16:7-13, 1970.
  pubmed

• 11) Hellstrom, I., Hellstrom, K. E., Sjogren, H. O. and Warner, G. A.:Serum factors in tumor-free patients cancelling the blocking of cell-mediated tumor immunity. Int. J. Cancer, 8:185-191, 1971.
  pubmed

• 12) Simmons, R. L., Rios, A., Ray, P. K. and Landgren, G.:Effect of neuraminidase on growth of a 3-methylcholanthrene-induced fibrosarcoma in normal and immunosuppressed syngeneic mice. J. Natl. Cancer Inst., 47:1087-1094, 1971.

• 13) Sjogren, H. O., Hellstrom, I., Bansal, S. C. and Hellstrom, K. E.:Suggestive evidence that the blocking antibodies of tumor-bearing individuals may be antigen-antibody complexes. Proc. Natl. Acad. Sci., 68-1372-1375, 1971.
  pubmed

• 14) Bekesi, J. G., Arneault, G. St., Walter, L. and Holland, J. F.:lmmunogenicity of leukemia L 1210 cells after neuraminidase treatment. J. Natl Cancer Inst., 49:107-118, 1972.

• 15) Cooperband, S. R., Badger, A. M. and Davis, R.:The effect of immunoregulatory alphaglobulin upon lymphocytes in vitro. J. Immunol., 109:154-163, 1972.

• 16) Currie, G. A. and Bacham, C.:Serum mediated inhibition of the immunological reactions of the patient to his own tumor:A possible role for circulating antigens. Br. J. Cancer, 26:427-438, 1972.

• 17) Baldwin, R. W., Bowen, J. G. and Price, M. R.:Detection of circulating hepatoma D23 antigen and immune complexes in tumor bearer serum. Br. J. Cancer., 28:16-24. 1973.
  pubmed

• 18) Alexander, P.:Escape from immune destruction by the host through shedding of surface antigens:Is this a characteristic shared by malignant and embryonic cells? Cancer Res., 34:2077-2082, 1974.

• 19) Cruse, J. M., Lewis, G. K., Whitten, H. D., Watson, E. S., Fields, J. F., Adams, S. T., Harvey III, G. F., Paslay, J. W. and Porter, M.:Mechanism of immunological enhancement. Immunology of Cancer Progr. Exp. Tumor Res., 19:110-156, 1974.

• 20) Hellstrom, K. E. and Hellstrom, I.:Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv. Immunol., 18:209-277, 1974.
  pubmed

• 21) Jose, D. G. and Seshadri, R.:Circulating immune complexes in human neuroblastoma:direct assay and role in blocking specific cellular immunity. Int. J. Cancer, 13:824-838, 1974.
  pubmed

• 22) Holland, J. F., and Bekesi, J. G.:Immunotherapy of human leukemia with neuraminidase-modified cells. Med. Clin. North Am., 60:539-549, 1976.
  pubmed

• 23) Tada, T., Taniguchi, M. and David, C. S.:Properties of the antigen-specific suppressive T-cell factor in the regulation of antibody response of the tumor. IV. Special subregion assignment of the gene that codes for the suppressive T-cell factor in the H-2 histcompatibility complex. J. Exp. Med., 144:713-725, 1976.

• 24) Spence, R. J., Simon, R. M., and Baker. A. R.:Failure of lmmuno-therapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst., 60:451-459, 1978.

18. 担癌体の免疫抑制

P.205 掲載の参考文献

• 1) 漆崎一朗, 後町洋一, 長井忠則, 西条登, 小山隆三, 福田守道:がん血清中のリンパ球のPHA反応抑制因子. 最新医学, 29:1775-1783, 1977.

• 2) 松田好史, 木本宏昭, 北目文郎, 石田名香雄:担癌マウス血清中に見い出された免疫抑制活性を示す酸性蛋白, 医学のあゆみ, 102:747-749, 1977.

• 3) 藤本重義:担癌生体における抑制性T細胞. 免疫(代謝) , 16:81-89 1979.

• 4) Gross, L.:"Spontaneous" leukemia developing in C3H mice following inoculation in infancy with AK-leukemic extracts or AK-embryos. Proc Soc. Exp. Biol. Med., 76:27-32, 1951.

• 5) Kamrin, B. B.:Successful skin homografts in mature non-littermate rats treated with fractions containing alpha-globulins. Pro. Soc. Exp. Biol. Med., 100:58-61, 1959.

• 6) Old, L. J., Boyse, E. A., Clark, D. A. and Carswell, E. A.:Antigenic properties of chemically induced tumors. Ann. N. Y. Acad. Sci., 101:80-106, 1962.

• 7) Trubowitz, S., Masek, B. and Del Rosario, A.:Lymphocytic response to phytohemagglutinin in Hodgkin's disease, lymphocytic leukemia and leukosarcoma. Cancer, 19:2019-2023, 1966.

• 8) Cooperband, S. R., Bondevik, H. E., Schmid, K. and Mannick, J. A.:Transformation of human lymphocytes:inhibition by homologous alpha-globulin. Science, 159:1243-1244, 1969.

• 9) Ashikawa, K., Inoue, K., Shimizu, T. and Ishibashi, Y.:An increase of serum alpha-globulin in tumor-bearing hosts and its immunological significance. Japan. J. Exp. Med., 41:339-355, 1971.

• 10) Prehn, R. T., and Lappe, M. A.:An immunostimulation theory of tumor development. Transplant. Rev., 7:26-54, 1971.
  pubmed

• 11) Vaage, J.:Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue. Cancer Res., 31:1655-1662, 1971.
  pubmed

• 12) Belebradek, J. Jr., Barski, G. and Tonier, M.:Evolution of cell-mediated antitumor immunity in mice bearing a syngeneic chemically induced tumor. Influence of tumor growth, surgical removal and treatment with irradiated tumor cells. Int. J. Cancer, 9:461-469, 1972.

• 13) Kobayashi, H., Kuzumaki, N., Gotohda, E., Takeichi, N., Sendo, F., Hosokawa, M. and Kodama, T.:Specific antigenicity of tumors and immunological tolerance in the rat induced by Friend, Gross, and Rauscher virus. Cancer Res., 33:1958-1603, 1973.

• 14) Youn, J. K., Lefrancois, D. and Barski, G.:In vitro studies on mechanism of the"eclipse" of cell-mediated immunity in mice bearing advanced tumors. J. Natl. Cancer Inst., 50:921-929, 1973.

• 15) Glasgow, A. H., Nimberg, R. B., Menzoian, J. O., Saporoushetz, I., Cooperband, S. R., Schmid, K. and Mannick, J. A.:Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer. New Eng. J. Med., 291:1263-1267, 1974.
  pubmed

• 16) Paranjpe, M. S. and Boone, C. W.:Kinetics of the antitumor delayed hypersensitivity response in mice with progressively growing tumors:stimulation followed by specific suppression. Int. J. Cancer, 13:179-186, 1974.
  pubmed

• 17) Kirchner, H., Muchmore, A. V., Chused, T. M., Holden, H. T. and Herberman, R. B.:Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J. Immunol, 114:206-210, 1975.

• 18) Klein, G.:Immunological surveillance against neoplasia. Harvey Lect. 69:71-102, 1975.

• 19) Dekers, P. J., Pardridge, D. H., Wang, B. S. and Mannick, J. A.:The specificity of concomitant tumor immunity at large tumor volumes. Cancer Res., 36:3690-3694, 1976.

• 20) Fujimoto, S., Greene, M. J. and Sehon, A. H.:Regulation of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. J. Immunol., 116:791-799, 1976.

• 21) Rao, V. S., Bagai, R. and Bonavida, B.:Specific enhancement of tumor growth and depression of cell-mediated immunity following sesitization to solulble tumor antigens. Cancer Res., 36:1384-1391, 1976.

• 22) Greene, M. I., Pierres, A., Dorf, M. and Benacerraf, B.:The I-J subregion coded for determinants on suppressor factor(s) which limit the contact sensitivity response to picrylchloride. J. Exp. Med., 146:293-299, 1977.

• 23) Cohen, I. R., Livnat, S and Waksal, S. D.:Initiator and recruited T lymphocytes are distinct subclasses of T lymphocytes. Eur. J. Immunol., 8:35-41, 1978.
  pubmed

• 24) Minami, A., Mizushima, Y., Takeichi, N., Hosokawa, M. and Kobayashi, H.:Dissociatien of anti-tumor immune responses in rats immunized with solublized tumor associated antigens from a methylcholanthrene-induced fibrosarcoma. Int J. Cancer, 23:358-365, 1979.
  pubmed

19. 癌と免疫異常症

P.217 掲載の参考文献

• 1) 葛巻暹, 武市紀年, 小林博:自己免疫疾患と癌-特にウイルス感染の役割. 最新医学, 27:315-325, 1972.

• 2) 小林博, 葛巻暹:免疫とウイルス. 医学のあゆみ, 31:12-17, 1973.

• 3) 葛巻暹, 小林博:腫瘍ウイルスと自己免疫病. 医学のあゆみ, 91:699-704, 1974.

• 4) 葛巻暹:自己免疫疾患と人癌. 腫瘍免疫学(小林, 橘編) , 403-409, 朝倉書店, 1974.

• 5) 鈴木司郎, 小島秀男:Slow virus infectionの免疫病理. 医学のあゆみ, 90:538-542, 1974.

• 6) 武市紀年:GVH反応, 腫瘍免疫学 (小林, 橘編) , 250-253, 朝倉書店, 1974.

• 7) 武市紀年:生体の免疫応答に影響する発癌関連因子ウイルス, 腫瘍免疫学 (小林, 橘編) 145-150, 朝倉書店, 1974.

• 8) 早川 浩, 飯塚伸子, 小林登:厚生省特定疾患. 免疫不全症候群調査研究班. 昭和51年度研究報告書, 7, 1977.

• 9) 伊藤和彦:原発性免疫不全と酵素異常. 日本臨床, 36:108-109, 1978.

• 10) 稲井真弥:先天性補体欠損症. 日本臨床, 36:114-115, 1978.

• 11) 小高 健:マウス白血病ウイルスと宿主遣伝子の関係. 蛋白質・核酸・酵素, 23:127-136, 1978.

• 12) 早川 浩, 小林登:原発性免疫不全症候群と難病. 日本臨床, 36:104-105, 1978.

• 13) 山名征三, 中村善一, 大藤 真:ヒト疾患における抗リンパ球抗体. 臨床免疫, 10:1-7, 1978.

• 14) 板倉克明:ミンクアリューシャン病. 免疫病理学的疾患(岡林編) 570-577, 文光堂, 1979.

• 15) 右田俊介:実験的形質細胞腫. 免疫病理学的疾患(岡林編) , 617-630, 文光堂, 1979.

• 16) 小林博, 葛巻暹, 武市紀年, 小玉孝郎:異物化病. 免疫病理学的疾患(岡林 編) , 559-569, 文光堂, 1979.

• 17) 志方俊夫:ウイルス性肝炎, 免疫病理学的疾患(岡林編) , 361-378, 文光堂, 1979.

• 18) 白井俊一:New Zealandマウスの免疫病. 免疫病理学的疾患(岡林編) , 588-605, 文光堂, 1979.

• 19) 西塚泰章::SL/Niマウス. 免疫病理学的疾患(岡林編) , 578-587, 文光堂, 1979.

• 20) Isacson, P.:Myxoviruses and autoimmunity. Progr. Allergy, 10:256-292, 1967.

• 21) Kersey, J. H., Spector, B. D. and Good, R. A.:Primary immunodeficiency diseases and cancer:The Immunodeficiency-Cancer Registry. Int. J. Cancer, 12:333-347, 1973.

• 22) Benveniste, R. E. and Todaro, G. J.:Evolution of type C viral genes:evidence for an Asian origin of man. Nature, 261:101-108, 1976.
  pubmed

• 23) Kimberlin, R. H. ed. Slow virus diseases of animals and man. North-Holland Publishing Co. Amsterdam, 1976.

• 24) Bach, F. H.:The major histocompatibility complex and its relationship to autoimmune disease. In Autoimmunity. Talal, N. ed. pp. 4-32, Academic press, New York, 1977.

• 25) Glass, D. and Schur, P. H.:Autoimmunity and systemic lupus erythematosus. In Autoimmunity. Talal, N. ed. pp. 532-568, Academic Press, New York, 1977.

• 26) Klein, G. and Klein, E.:Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors:Contrasting consequences of host versus tumor evolution. Proc. Nat. Acad. Sci. USA 74:2121-2125, 1977.
  pubmed

• 27) Levy, J. A.:C-type RAN viruses and autoimmune disease. In Autoimmunity. Talal, N. ed. pp. 404-453, Academic Press, New York, 1977.

• 28) Talal, N.:Autoimmunity and lymphoid malignancy:Manifestations of immunoregulatory disequilbrium. In Autoimmunity. Talal, N. ed. pp. 184-206, Academic Press, New York, 1977.

• 29) Markenson, J. A. and Phillips, P. E.:Type C viruses and systemic lupus erythematosus. Arthritis and Rheumatism 21:266-270, 1978.
  pubmed

• 30) Penn, I.:Immunosuppression and malignant disease. In The Immunopathology of Lymphoreticular Neoplasms. Twomey, J. J. and Good, R. A. ed. pp. 223-237, Plenum Medical Book Co., New York, 1978.

20. 人癌の免疫学的診断

P.233 掲載の参考文献

• 1) 藤井源七郎他(編) :人癌と免疫-その基礎と臨床-, ライフサイエンス, 東京, 1976.

• 2) Herberman, R. B. (ed.) :Immunologic approaches to the diagnosis of cancer. Cancer, 37:549-562, 1976.

• 3) Abraham, G. E. (ed.) :Handbook of Radioimmunoassay. Marcel Dekker, New York, 1977.

• 4) Herberman, R. B. (ed.) :Immunodiagnosis of Human Cancer. Elsevier, New York-Amsterdam-Oxford, 1979.

21. 癌患者の免疫能

P.247 掲載の参考文献

• 1) 北郷修:予防接種とアトピー性皮膚炎. 小児科診療, 36:546-552, 1973.

• 2) 菊地浩吉, 金谷隆, 山岡博他:人癌患者における細胞性免疫. 医学のあゆみ, 91:394-399, 1974.

• 3) 橘武彦:ヒトのT cellとB cellの分離法ならびにSurface markerによる数の算定法. 日本臨床, 33:221-233, 1975.
  Medical*Online

• 4) 漆崎一朗:血清中の免疫抑制因子. Minophagen Medical Review, 22:260-270, 1977.

• 5) 小林博, 細川真澄男, 水島豊:癌免疫皮膚反応. 日本医事新報, No. 2805, 8-12, 1978.

• 6) 新保敏和, 麦谷星夫, 柿原歌子他:癌患者にみられるリンパ球とマクロファージの異常. 癌と化学療法, 5:261-272, 1978.

• 7) 珠玖洋, 高橋利忠:ヒトの癌細胞抗原. 代謝, 15:10月臨時増刊号, 1523-1563, 1978.

• 8) 仙道富士郎:Natural Killer. 代謝, 15:10月臨時増刊号, 免疫'78, 1421-1429, 1978.

• 9) 細川真澄男, 水島豊:免疫学的モニター最近の話題-皮膚反応テスト. 臨床外科, 33:1397-1402, 1978.

• 10) 柴田芳実, 田村啓二, 上永吉敏他:癌患者血清中に存在する免疫抑制酸性蛋白質(IAP) について III. IAPによる癌増殖促進作用, 日本免疫学会総会記録, 9:189-190, 1979.

• 11) 矢田純一:IgMないしIgGに対するレセプターの存在とT細胞サブセット- Tμ細胞, Tγ細胞-, 代謝, 16:11月臨時増刊号, 免疫'79, 1935-1940, 1979.

• 12) Morton, D. L., Eilber, F. R., Joseph, W. L. et al.:Immunological factors on human sarcomas and melanomas:A rational basis for immunotherapy. Ann. Surg. 172:740-749, 1970.
  pubmed

• 13) Takasugi, M. and Klein, E.:A microassay for cell-mediated immunity, Transplant. 9:219-227, 1970.

• 14) Hellstrom, I., Warner, G. A., Hellstrom, K. E. et al.:Sequential studies on cell-mediated immunity and blocking serum activity in ten patients with malignant melanoma. Int. J. Cancer, 11:280-292, 1973.
  pubmed

• 15) Hellstrom, I., Hellstrom K. E., Sjogren, H. O. et al.:Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int. J. Cancer, 7:1-16, 1971.
  pubmed

• 16) Morton, D. L, Holmes, E. C., Eilber, F. R. et al.:Immunological aspects of neoplasia:A rational basis for immunotherapy. Ann. Internal Med., 74:587-604, 1971.

• 17) Mavligit, G. M., Ambus, U., Gutterman, J. U. et al.:Antigen solubilized from human solid tumors:Lymphocyte stimulation and cutaneous delayed hypersensitivity, Nature, New Biol., 243:188-190, 1973.
  pubmed

• 18) Irie, F. R., Irie, K. and Morton, D. L.:A membrane antigen common to human cancer and fetal brain tissue. Cancer Res., 36:3510-3517, 1976.

• 19) Nakajima, T., Gonmari, M., Iwaguchi, T. et al:In vivo and in vitro cell-mediated immune reactions to autochthonous tumor extracts in patients with gastric cancer. Gann, 67:537-547, 1976.

• 20) Urist, M. M., Boddie, A. W., Holmes, E. C. et al.:Capillary tube leukocyte adherence inhibition:An assay for cell-mediated immunity in Cancer patients. Int. J. Cancer, 17:338-341, 1976.
  pubmed

• 21) Yasumoto, K., Ohta. M. and Nomoto, K.:Cytotoxic activity of lymphocyte to bronchogenic carcinoma cells in patients with lung cancer. Gann, 67:505-511, 1976.
  pubmed

• 22) Dostalova, O., Wagnerova, V. Schon, E. et al:Immunoglobulin levels and metastases of malignant tumors:Serum immunoglobulin levels in Cancer patients. Neoplasma, 24:177-191, 1977.
  pubmed

22. 癌の免疫療法の概念

P.262 掲載の参考文献

• 1) 東市郎, 坂谷光則, 山村雄一:結核菌菌体成分による癌の免疫療法. 人癌と免疫(藤井他編) , 253-270, ライフ・サイエンス, 東京, 1976.

• 2) 山脇幹夫:その他の細菌を用いる癌の免疫療法-Corynebacterium parvumを中心に-, 人癌と免疫(藤井他編) , 270-277, ライフサイエンス, 東京, 1976.

• 3) 塚越茂:植物多糖体など天然高分子物質を用いる試み. 人癌と免疫(藤井他編) , 296-303, ライフサイエンス, 東京1976.

• 4) 木村郁郎:OK-432による免疫療法. 癌の臨床, 24:428-433, 1978.

• 5) 小林博, 武市紀年, 三浪明男:腫瘍細胞抗原による免疫療法. 癌の臨床, 24:395-404, 1978.

• 6) 服部孝雄, 峠哲哉, 山県司政他:嫌気性コリネによる免疫療法. 癌の臨床, 24:421-427, 1978.

• 7) 福島松郎:特集/今日の癌免疫療法. 癌免疫・化学療法の実際-薬剤選択から成績まで-私の処方;特に特異的免疫療法を中心として. 臨外, 33:1411-1418, 1978.

• 8) 塩野谷博, 新井昌栄, 小柳望他:アブリンおよびリシン処理癌細胞による腫瘍免疫の誘導, 日本免疫学会総会記録, 9:191-192, 1979.

• 9) 鳥巣要道(編著) :癌免疫療法の臨床. ライフサイエンス, 東京, 1980.

• 10) 細川真澄男, 小林博:腫瘍免疫誘導抗原-その種類と増強-. 癌と化学療法, 7:1294-1303, 1980.
  Medical*Online

• 11) 湊長博, 狩野庄吾:NK-IFNシステム=その制御と生体内での役割についての最近の知見-. 日本臨免会誌, 4:1-12, 1981.

• 12) Alexander, P., Delorme, E. J., Hamilton, L. D. et al.:Effect of nucleic acids from immune lymphocytes on rat sarcoma. Nature (Lond.) , 213:569-572, 1967.
  pubmed

• 13) Krementz, E. T. and Samuels, M. S.:Tumor cross-transplantation and cross-transfusion in the treatment of advanced malignant disease. Bull. Tulane Univ. Med. School, 26:263-1967.

• 14) Glynn, J. P., Halpern, B. L. and Fefer, A.:An immunochemotherapeutic system for the treatment for the transplanted Moloney virus-induced lymphoma in mice. Cancer Res., 29:515-520, 1969.
  pubmed

• 15) Mathe, G., Pouillart, P. and Lapeyraque, F.:Active immunotherapy of 1210 leukemia applied after the graft of tumor cells. Brit. J. Cancer, 423:814-824, 1969.

• 16) Nadler, S. H. and Moore, G. E.:Immunotherapy of malignant disease. Arch. Surg., 99:376-381, 1969.
  pubmed

• 17) Hellstrom, K. E., Hellstrom, I. and Sjogren, H. O.:Serum mediated inhibition of cellular immunity to methylcholanthrene induced murine sarcoma, Cell. Immunol. 1:18-30, 1970.
  pubmed

• 18) Moore, G. E. and Gerner, R. E.:Cancer immunity:Hypothesis and Clinical trial of lymphocytotherapy for malignant disease. Ann. Surg., 172:733-739, 1970.
  pubmed

• 19) Zbar, B., Bernstein, L. D., Tanaka, T. et al.:Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycbocterium bovis strain BCG. Science, 170:1217-1218, 1970.

• 20) Alexnder, P. and Delorme, E. J.:The use of irradiated lymphoid cells for immunotherapy of primary tumors in rats. Israel J. Med. Sci., 7:239, 1971.

• 21) Fefer, A.:Adoptive chemoimmunotherapy of a Moloney lymphoma. Int. J. Cancer, 8:364-373, 1971.
  pubmed

• 22) Hellstrom, L, Hellstrom, K. E., Sjogren, H. O. et al.:Serum factors in tumor-free patients cancelling the blocking of cell-mediated tumor immunity, Int. J. Cancer, 8:185-191, 1971.

• 23) Humphery, J. L., Jewell, W. R., Murry, D. R. et al.:Immunotherapy for the patient with cancer, Ann. Surg., 173:47-54, 1971.

• 24) Zbar, B., Bernstein, I. D. and Rapp, H. J.:Suppression of tumor growth ot the site of infection with living Bacillus Calmette-Guerin, J. Nat. Cancer., Inst., 46:831-839, 1971.

• 25) Cheema, R. A. and Hersh, E. M.:Local tumor immunotherapy with in vitro activated autochthonous lymphocytes. Cancer, 29:982-986, 1972.

• 26) Katz, D. H., Ellman, L., Paul, W. E. et al.:Resistance of guinea pigs to leukemia fallowing transfer of immnunocompetent allogeneic lymphoid cells. Cancer Res., 32:133-140, 1972.

• 27) Kassel, R. L., 0ld, L. J., Carswell, E. A. et al.:Serum mediated leukemia cell destruction in AKR mice-Role of complement in the phenomenon-J. Exp. Med., 138:925-938. 1973.

• 28) Tripodi, D., Parks, L. C. and Brugmans, J.:Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. N. Engl. J. Med., 289:354-357, 1973.
  pubmed

• 29) Bast, R. C. Jr., Zbar, B., Borsos, T. et al.:BCG and Cancer. New England J. Med., 290:1413-1420, 1458-1469, 1974.

• 30) Fidler, I. J.:Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages, Cancer Res., 34:1074-1078, 1974.
  pubmed

• 31) Johnson, F. L., Thomas, E. D., Bucker, C. D. et al.:The current status of bone marrow transplantation in cancer treatment. Cancer Treatment Rev., 1:81-97. 1974.

• 32) Kobayashi, H., Gotohda, E., Kuzumaki, N. et al.:Reduced transplantability of syngeneic tumors in rats immunized with allogeneic tumors. Int. J. Cancer, 13:-522-529, 1974.

• 33) LoBuglio, A. F. and Neidhart, J. A.:A review of transfer factor, Immunotherapy in cancer, Cancer, 34:1563-1570, 1974.

• 34) Maeda, Y. Y., Chihara, G. and Ishimura, K.:Unique increase of serum proteins and action of antitumour polysaccharides. Nature (Lond.) , 252:250-252, 1974.
  pubmed

• 35) Pilch, Y. H., Veltman, L. L. and Kern, D. H.:Immune cytolysis of human tumor cell mediated by xenogeneic immune RNA. Arch. Surg., 109:30-34, 1974.
  pubmed

• 36) Nomoto, K., Yoshikumi, C., Matsunaga, K. et al.:Restoration of antibody-forming capacities by PS-K in tumor bearing mice. Gann, 66:365-374, 1975.
  pubmed

• 37) Frester, J. H.:Phytohemagglutinin activated autochtonous lymphocytes for systemic immunotherapy of human neoplasmas. Ann. N. Y. Aca I. Sci., 277:45-51, 1976.

• 38) Hosokawa, M., Imamura, M., Oikawa, T. et al.:Inhibition of syngeneic tumor growth in rats immunized with allogeneic skin grafts. Int. J. Cancer. 18:369-374. 1976.
  pubmed

• 39) Rojas, A. F., Mickiewicz, E., Feierstein, J. N. et al.:Levamisole in advanced human breast cancer. Lancet 1:211-. 215, 1976.

• 40) Stewarrt, T. H. M., Hollinshead, A. C., Harris, J. E. et al.:Immuno-therapy of lung cancer. Ann. N. Y. Acad. Sci., 277. 436-466, 1976.

• 41) Takita, H., Minowada, J., Han, T. et al. Adjuvant immunotherapy in broncllogenic carcinoma. Ann. N. Y. Acad, Sci. 277:345-354, 1976.
  pubmed

• 42) Akiyama, J., Kawamura, T., Gotohda, E. et al.:Immunochemotherapy of transplanted KMT-17 in WKA rats by combination of cyclophosphamide and immunostimulatory protein-bound polysaccharide isolated from basidiomycetes. Cancer Res., 37:3042-3045, 1977.
  pubmed

• 43) Gresser, I.:Antitumor effects of interferon. in Cancer, 5:A comprehensive treatise chemotherapy pp. 521-571, Plenum Press, New York, 1977.

• 44) Oikawa, T., Hosokawa M., Imamura, M. et al.:Antitumor immunity by normal allogeneic blood transfusion in a rat. Clin. Exp. Immunol., 27:549-554, 1977.

• 45) Osborne, D. P. and Katz, D. H.:The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC-315, by the graft-vs-host reaction. J. Immunol., 118:1441-1448, 1977.
  pubmed

• 46) Oehler, R., Lindsay L. R., Herberman, R. B. et al.:Natural cell-mediated cytotoxicity in rats. II. In vivo augmentation of NK-cell activity, Int. J. Cancer, 21:210-220, 1978.

• 47) Bortin, M. M., Truitt, R. L., Rimm, A. A. et al.:Graft-versus. leukemia reactivity induced by alloimmunization without augmentation of graft-versus host reactivity. Nature (Lond.) , 281:490-491, 1979.
  pubmed

• 48) Fish, D. C., Gilden, R. V., Huebner, R. J. et al.:Prevention of spontaneous leukemia AKR mice by passive immunization and type specifity of this protection, J. Natl. Cancer Inst., 62:942-945, 1979.

• 49) Truitt, R. T., Bortin, M. M., Blasecki, J. W. et al.:Allosensitization:Induction of antileukemic reactivity without modification of antihost reactivity in H-2 campatible mice. Proc. AACR and ASCO, 20:133, 1979.

• 50) Weiden, P. L., Flournoy, N., Fefer, A. et al.:Antileukemic effect of graft-versus-host disease (GvHD) in human recipients of allogeneic marrow grafts, Proc. AACR and ASCO, 20:325, 1979.

• 51) Zarling, J. M. and Bach, F. H.:Continuous culture of T cell cytotoxic for autologous human leukemia cells, Nature (Lond.) , 280:685-688, 1979.
  pubmed

• 52) Fernandez-Cruz, E., Wada, B. A. and Feldman, J. D.:Elimination of syngeneic sarcoma in rats by subset of T lymphocytes. J. Exp. Med., 152:828-841, 1980.

• 53) Nadler, L. M, Stashenko, P., Hardy, R. et al:Serotheray of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res., 40:3147-3154, 1980.
  pubmed

• 54) Olsen, G. A., Glasgow, L. A. and Dethlefsen, L. A.:Alteration of murine mammary tumor metastasis and growth by cytomegalovirus infection. Cancer Res., 40:853-860, 1980.
  pubmed

• 55) Yamada, Y., Kawamura, T., Gotohda, E. et al.:Effect of nomal allogeneic lymphoid cell transfer in combination with chemotherapy on a trans. plantable tumor in rats. Cancer Res., 40:954-958, 1980.

23. 癌の免疫療法の実際

P.279 掲載の参考文献

• 1) 三井清文:リンパ球移入による免疫療法. 薬物療法, 9:917-926, 1976. 服部孝雄, 新本稔, 山県司政他:癌免疫化学療法の実際-薬剤選択から成績まで-私の処方;OK-432腫瘍内大量投与, 臨床外科, 33:1433-1440, 1978.

• 2) 大森幸夫, 本田一郎, 高橋秀禎他:局所進展乳癌に対する複合療法としてのOK-432 (ピシバニー. ル) の腫瘍内投与. 癌と化学療法, 7:283-292, 1980.
  Medical*Online

• 3) 岸本進, 河野文夫, 松崎博充:腫瘍免疫療法の臨床. 癌と化学療法, 7:2029-2038, 1980.
  Medical*Online

• 4) 鳥巣要道編著:癌免疫療法の臨床. pp. 117-173, ライフサイエンス, 東京, 1980.

• 5) Coley, W. B.:The therapeutic value of the mixed toxins of the Streptococcus of erysipelas and Bacillus prodigiosus in the treatment of inoperable tumors with a report of 160 cases. Amer. J. Med. Sci., 112:251, 1896.

• 6) Mathe, G., Amiel, J, L., Schwarzenberg, L. et al.:Active immunotherapy for acute Lymphoblastic leukemia, Lancet, 1:697-699, 1969.
  pubmed

• 7) Nadler, S. H. and Moore, G. E.:Immunotherapy of malignant disease. Arch. Surg., 99:376-381, 1969.
  pubmed

• 8) Morton, D. L., Eilber, F. R., Malmgrem, R. A. et. al.:Immunological factors which influence response to immunotherapy in malignant melanoma, Surg., 68:158-164, 1970.

• 9) Kremenz, E. T., Samuels, M. S., Wallace, J. H. et al.:Clinical experiences in immunotherapy of cancer. Surg. Gyneol. Obstet., 133:209-217, 1971.

• 10) Marcove, R. C., Southam, C. M., Levin, A. et al:A clinical trial of autogeneous vaccine in osteogenic sarcoma in patients under age of twentyfive. Surg. Forum. 22:434-435, 1971.

• 11) Stjernsward, J. and Levin, A.:Delayed hypersensitivity-induced regression of human neoplasms. Cancer, 28:628-640, 1971.
  pubmed

• 12) Cheema, A. R. and Hersh, E. M.:Local tumor immunotherapy with in vitro activated autochthonous lymphocytes. Cancer, 29:982-986, 1972.

• 13) Klein, E. and Holtermann, O. A.:Immunotherapeutic approches to the management of neoplasms. Natl. Cancer Inst. Monogr., 35:276, 1972.

• 14) Leventhal, B. G., LePourhiet, A., Herberman, R. B. et al.:Immunotherapy in previously treated acute lymphatic leukemia. Natl. Cancer. Inst. Monogr., 39:177-187, 1973.
  pubmed

• 15) Powles, R. L., Growther, D., Bateman, C. J. T. et al.:Immunotherapy for acute myelogenous leukemia, Br. J. Cancer, 28:365-376, 1973.

• 16) Amery, W., Swierenga, J., Gooszen, H. C. et al.:Immunopotentiation with levamisole in resectable bronchogenic carcinoma:A double-blind controlled trial. Br. Med. J., 3:461-464, 1975.

• 17) Eilber, F. R., Townsend, C. M. Jr. and Morton, D. L:Osteosarcoma:Results of treatment employing adjuvant immunotherapy, Clin Orthop. Relat. Res., 111:94-100, 1975.

• 18) Israel, L. and Edelstein, R.:In Immunological Aspect of Neoplasia. pp. 485-504, Williams and Wilkins, Baltimore, 1975.

• 19) Gutterman, J. U., Mavligit, G. M., Burgess, M. A. et al.:Immunotherapy of breast cancer, malignant melanoma and acute leukemia with BCG:Prolongation of disease-free interval and survival. Cancer. Immunol. Immunother., 1:99-107. 1976.

• 20) Holland, J. F. and Bekesi, J. G.:Immunotherapy of hunlan leukemia with neuraminidase-modified cells. Med. Clin. North. Am., 60:539-549, 1976.
  pubmed

• 21) Kimura, I., Ohnoshi, T., Yasuhana, S. et al.:Immunochemotherapy in human lung cancer using the streptococcal agent OK-432. Cancer, 37:2201-2203, 1976.

• 22) LoBuglio, A. F. and Neidhart, J. A.:Transfer factor:A potential agent for cancer therapy. Med. Clin. North. Am., 60:585-590, 1976.
  pubmed

• 23) McKenally, M. F., Maver, C. and Kausel, H. W.:Regoinal immunotherapy of lung cancer with intrapleural BCG. Lancet, 1:377-379, 1976.

• 24) Rojas, A. F., Feierstein, J. N., Mickiewicz, E. et al.:Levamisole in advanced human breast cancer. Lancet, 1:211-215, 1976.
  pubmed

• 25) Dimitrov, N. V., Singh, T. and Balcueva, E.:Intralesional inlections of C. parvum in local skin recurrence of breast cancer. Proc. Am. Asoc. Clin. Oncol., 18:270, 1977.

• 26) Hersh, E. M, Mavligit, G. M, Gutterman, J. U. et al.:Immunotherapy of human cancer. In Cancer ed. Becker, F. F. 6:pp. 425-532, Plenum Press, New York, 1977.

• 27) Strander, H. and Einhorn, S.:Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int. J. Cancer, 19:468-473, 1977.

• 28) Gee, T. S., Bowling, M. D., Cunningham, I. et al.:Evaluation of pseudomonas aerugiosa vaccine for prolongation of remission in adults with acute nonlymphoplastic leukemia treated with the L-12 Protocol:A preliminary report. In Immunotherapy of Cancer:Present Status of Trials in Man. ed. Terry, W. D. and Windhorst, D., pp. 415-422, Raven Press, New York, 1978.

• 29) Goodnight, J. E. Jr. and Morton, D. L.:Immunotherapy for malignant disease. Ann. Rev. Med., 29:231-283, 1978.
  pubmed

• 30) Ohno, R., Ueda, R., Imai, K. et al.:A clinical trial of cell-wall skeleton of BCG in chemoimmunotherapy of acute leukemia, Gann, 69:179-186, 1978.

• 31) Reizenstein, P., Brenning, G., Engstedt, L. et al.:Effect of immuno-therapy on survival and remission duration in acute non-lymphatic leukemia, In Immunotherapy of Cancer:Present Status of Trials in Man. ed. Terry, W. D. and Windhorst, D., pp. 329-339, Raven Press New York, 1978.

• 32) Stewart, T. H. M., Hollinshead, A. C., Harris, J. E. et al.:Survival study of immullochemotherapy in lung cancer. In Immunotherapy of Cancer:Present Status of Trials in Man. ed. Terry, W. D. and Windhorst, D., pp. 203-216, 1978. Raven Press, New York, 1978.

• 33) Takita, H, Takada, M., Minowada, J. et al.:Adjuvant immunotherapy of stage III lung carcinoma. In Immunotherapy of Cancer;Present Status of Trials in Man. ed. Terry, W. D. and Windhorst. D., pp. 217-223, Raven Press, New York, 1978.

• 34) Yamamura, Y., Sakatani, M., Ogura, T. et al.:Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS) . Cancer, 43 :1314-1319, 1979.
  pubmed

• 35) Yasumoto, K., Manabe, H., Yamagawa, E. et al:Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of mycobacterium bovis Bacillus Calmette-Guerin. Cancer Res., 39:3262-3267, 1979.

• 36) Miwa, H., Ono, F., Orita, K. et al.:Immunochemotherapy of gastric cancer with levamisole. Acta Med. Okayama, 34:275-281, 1980.
  pubmed

24. 癌の免疫外科

P.289 掲載の参考文献

• 1) 湯村正仁他:癌免疫療法(2) 脾合併切除を併用した癌免疫療法の可能性について. 日外会誌, 76:1076, 1975

• 2) 折田薫三:癌の手術と免疫療法. 外科治療, 35:379, 1976.

• 3) 梶谷鐶, 高木国夫:胃癌根治手術とその遠隔成績. 外科治療, 39:679, 1978.

• 4) 山下徹郎, 早川邦雄他:Cryosurgeryによる癌細胞の転移促進. 癌と化学療法, 5:110, 1978.

• 5) 小林博, 加藤紘之他:癌の免疫外科. 外科, 41:1301, 1979.

• 6) 鈴木磨郎, 堀勝義他:腫瘍内微少循環の特性-原発腫瘍およびリンパ節転移巣における検討. 日本癌学会総会記事, 1096:298, 1979.

• 7) 小玉孝郎他:実験的癌肺転移の免疫学的退縮に果たすマクロファージの役割. 日本肺癌学会総会記事 Supplement, 62, 1980.

• 8) Old, L. J., Clarke, D. A.:Effect of prior splenectomy on the growth of sarcoma 180 in normal and bacillus calmette guerin infected mice. Experientia, 18:335, 1962.
  pubmed

• 9) Gershon, R. K. et al.:Immunologic defenses against metastases. Impairment by excision of an allotransplanted lymphoma, Science. 159:646, 1967.

• 10) Ferrer, J. F.:Enhancement of the growth of sarcoma 180 in splenectomized and sham operated AKR mice. Transplantation, 6:160, 1968.
  pubmed

• 11) Helltrom, I. et al.:Cellular and humoral immunity to different types of human neoplasms. Nature, 220:1352, 1968.
  pubmed

• 12) Bard, D. S., Pilch, Y. H.:The role of the spleen in the immunity to a chemically induced sarcoma in C3H mice. Cancer Res., 29:1125, 1969.
  pubmed

• 13) Barski, G., Youn, J. K.:Evolution of cell-mediated immunity in mice bearing an antigenic tumor. J. Natl. Cancer Inst., 43:111, 1969.
  pubmed

• 14) Gershon, R. K., Carter, R. L.:Factors controlling cocomitant immunity in tumor bearing hamsters. Effects of prior splenectomy and tumor removal. J. Natl. Cancer Inst., 43:533, 1969.

• 15) Abrin, R. J.:Prospects for cryoimmunotherapy in case of metastasizing carcinoma of the prostata. Cryobiology, 8:271, 1971.

• 16) Crile, G., Deodbar, S.:Role of preoperative irradiation in prolonging concomitant immunity and preserving metastasis in mice. Cancer, 27:629, 1971.

• 17) Fisher, B., Fisher, E. R.:Studies concerning the regional lymph node in cancer. Cancer, 27:1001, 1971.
  pubmed

• 18) Heppner, G. H.:In vitro studies on cell mediated immunity following surgery in mice sensitized to syngeneic mammary tumors. Int. J. Cancer, 9:119, 1972.
  pubmed

• 19) Milas, L., Mujagic. H.:The effect of splenectomy on fibrosarcoma"metastasis"in lungs of mice. Int. J. Cancer, 11:186, 1973.
  pubmed

• 20) Scovill, W. A., Saba, T. H.:Humoral recognition deficiency in the etiology of reticuloendothelial depression induced by surgery. Ann. Surg., 178:59, 1973.

• 21) Eccles, S. and Alexander, P.:Macrophage content of tumors in relation to metastatic spread and host immune reaction. Nature, 250:667-669, 1974.
  pubmed

• 22) Fidler, I. J.:Immune stimulation-inhibition of experimental cancer metastases. Cancer Res., 34:491, 1964.

• 23) Kodama, T., Gotoda, E., Takeichi, N. and Kobayashi, H.:Histopathology of immunologic regression of tumor metastasis in the lymph nodes. J. Natl Cancer Inst., 52:931-939, 1974.
  pubmed

• 24) Morton, D. L., Sparks, F. C.:Oncology, "Principles of surgery"ed. by Schwartz, S. 1., 1974.

• 25) Rios, A., Simmons, R.:Active specific immunotherapy of minimal residual tumor:Excision plus neuraminidase-treated tumor cells. Int. J. Cancer., 13:71, 1974.
  pubmed

• 26) Whitney, R. B., Levy, J. G.:Suppression of mitogen responses by serum from tumor-bearing mice. Europ. J. Cancer, 10:739, 1974.

• 27) Kobayashi, H., Gotohda, E. et al.:Inhibition of metastasis in rats immunized with xenogenized autologous tumor cells after excision of the primary tumor. J. Nat. Cancer Inst., 54:997, 1975.
  pubmed

• 28) Slade, M. S., Simmons, R. L. et al.:Immunodepression after major surgery in normal patients, J. A. M. A., 178:556, 1975.

• 29) Currie, G.:Immunological aspects of host resistance to the development and growth of cancer, Biophysica. Acta., 458:135, 1976.

• 30) Whitney, R. B., Pope, B. L.:Immune competence and immunosuppressive factors in splenectomized tumor bearing mice. Cell Immunol., 28:15, 1977.
  pubmed

• 31) Gascoyne, R. D., Whitney, R. B.:Recovery of immune competence after tumor resection in mice. Brit. J. Cancer, 37:190, 1978.

• 32) Caldwell, W. L.:Clinical instrumentation requirements with a review of the hyperthermia experience. Cancer Res., 39:2332, 1972.

• 33) Storm, F. K., Harrison, W. H. et al.:Normal tissue and solid tumor effects of hyperthermia in animal models and clinical trial. Cancer Reserch, 39:2245, 1979.

• 34) Hanna, N. and Fidler, I. J.:Role of natural killer cells in the destruction of circulating tumor cells. J. Natl. Cancer Inst., 65:801-809, 1980.
  pubmed

25. 癌の免疫放射線療法

P.298 掲載の参考文献

• 1) 大星章一, 下里幸雄, 板倉克明, 梅垣洋一郎:癌放射線療法の病理(I) 癌細胞の治癒過程の組織学的追跡, 医学のあゆみ, 61:618-625, 1967a.

• 2) 大星章一, 下里幸雄, 板倉克明, 梅垣洋一郎:癌放射線療法の病理(II) 癌組織の治癒過程におけるリンパ球様細胞反応の免疫学的意義. 医学のあゆみ, 61:725-730. 1967 .

• 3) 下里幸雄:放射線治療の病理. 癌・放射線療法, 医歯薬出版, 東京, 1969.

• 4) 下里幸雄, 永井完治, 池内駿之:腫瘍免疫と放射線治療-その基礎-. 癌・放射線療法, p. 21-26, 篠原出版, 東京, 1987.

• 5) Puck, T. T. and Marcus, P. I.:Action of X-ray on mammalian cells. J. Exp. Med., 103:653-666, 1956.

• 6) Cohen, A. and Cohen, L.:Estimation of the cellular lethal dose for the C3H mouse mammary carcinoma from radiosensitivity studied in vivo. Nature, 185:262-263, 1960.

• 7) Powers, W. E., Palmer, L. A. and Tolmach, L. J.:Cellular radiosensitivity and tumor curability. Natl. Cancer Inst. Monogr., 24:169-185, 1967.
  pubmed

• 8) Crile, G. J r. and Deodhar, S. D.:Role of preoperative irradiation in prolonging concomitant immunity and preventing metastasis in mice. Cancer, 27 :629-634, 1971.

• 9) Proceedings of the European Society for Radiation Biology. Brit. J. Cancer, 32:752-769, 1975.

• 10) Takeichi, N., Economou, G. C. and Boone, C. W.:Accelerated regeneration of trypsin-treated surface antigens of simian virus-40 transformed BALB/ 3T3 cells induced by X-irradiation. Cancer Res., 36:1258-1262, 1976.
  pubmed

• 11) Minami, A., Mizushima. Y., Hosokawa, M., Takeichi, N. and Kobayashi, II.:Dissociation of antitumor immune responses in rats immunized with solubilized tumor-associated antigens from a methylcholanthrene-induced fibrosarcoma. Int. J. Cancer, 23:358-365, 1979.

• 12) Minami, A., Kasai, M., Mizushima, Y., Takeichi, N., Hosokawa, M. and Kobayashi, H.:Characterization of immunosuppressor cells in rats immunized with solubilized tumor-associated antigens prepared from a methylcholanthrene-induced fibrosarcoma. Cancer Res., 40:2129-2134, 1980.
  pubmed

26. 癌の免疫化学療法

P.304 掲載の参考文献

• 1) 松本雄雄:薬物による免疫抑制について. 総合臨床, 19:1483-1490, 1970.

• 2) 秋吉毅, 川口満宏, 辻秀男:制癌剤の細胞性免疫におよぼす影響の検討におけるcytotoxicity testの応用, 第2報. 癌の化学療法, 3:1205-1211, 1976.

• 3) 東海胃癌術後免疫化学療法共同研究班:進行胃癌の術後免疫化学療法に関する研究. 癌と化学療法, 3:715-721, 1976
  Medical*Online

• 4) 安元公正, 真鍋英夫, 植田美彦他:免疫学的, 病理学的にみたBGC-CWSによる肺癌の免疫療法の効果. 日本癌学会総会記事, 36:952, 1977.

• 5) 前川勲, 川村詔導, 岡部実裕, 今村雅寛, 白石忠雄:PSKによる急性白血病の免疫療法の試み. 癌と化学療法, 6:611-617, 1979.
  Medical*Online

• 6) 山田雄次, 北里健二, 釆見憲男:Futrafulとクレスチンの合併効果の検討. 癌と化学療法, 6:127-131, 1979.

• 7) 水島豊:抗白血病剤busulfanによるラットの抗腫瘍移植抵抗性の増強. 北海道医学雑誌, 55:537-542, 1980.

• 8) 塚田裕:抗体と結合させた制癌剤による肝癌の治療. 医学のあゆみ, 117:13-14, 1981.

• 9) Mathe, G., Loc, T. B. and Bernard, J. C.:Effect sur la leucemie 1210 de la souris d'un combination par diazotation d:Amethopterine et de-globulin de hamsters porteurs de cette leucemie par hetirograffe. C. R. Acad. Sci., 246:1626-1628, 1958.

• 10) Ferrer, J. F. and Mihich, E.:Prevention of therapeutically induced regression of sarcoma 180 by immunologic enhancement. Cancer Res., 28:245-250, 1968.
  pubmed

• 11) Amiel, J. L.:Chemotherapy and immune reactions. Scientific Basis of Cancer Chemotherapy (Recent Results in Cancer Res.) ed. by Mathe, G. Springer-Verlag, Berlin, Heldelberg, N. Y., p. 41-53, 1969.

• 12) Floersheim, G. L.:A comparative study of the effects of antitumor and immunosuppressive drugs on antibody-forming and erythropoietic cells. Clin. exp. Med., 6:861-870, 1970.

• 13) Mihich, E., Bross, I., Mihich, M. and Nichlo, M.:A model system for detecting drug impairment of anti-tumor host defense. Cancer Res., 30:1376-1386, 1970.

• 14) Borella, L. and Webster, R. G.:The immunosuppressive effects of long-term combination chemotherapy in children with acute leukemia in remission. Cancer Res., 31:420-426, 1971.
  pubmed

• 15) Cheema, A. R. and Hersh, E. M.:Patients survival after chemotherapy and its relationship to in vitro lymphocyte blastogenesis. Cancer, 28:851-855, 1971.
  pubmed

• 16) Morton, D. L.:NIH conferance. Immunological aspects of neoplasia:A rational basis for immunotherapy. Ann. Int. Med., 74:587-604, 1971.

• 17) Pearson, J. W., Pearson, G. R., Gibson, W. T., Chermann, J. C. and Chirigos, M. A.:Combined chemoimmunostimulation therapy against murine leukemia. Cancer Res., 32:904-907, 1972.
  pubmed

• 18) Sinkovics, J. G., Cabiness, J. R. and Shullenberger, C. C.:Disappearance after chemotherapy of blocking serum factors as measured in vitro with lymphocytes cytotoxic to tumor cells. Callcer, 30:1428-1437, 1972.
  pubmed

• 19) Turk, J. L, and Poulter, L. W.:Selective depletion of lymphoid tissue by cyclophosphamide. Clin. Exp. Immunol., 10:285-296, 1972.
  pubmed

• 20) Davies, D. A. L. and O'Neill, G. J.:In vivo and in vitro effects of tumor specilic antibodies with chlorambucil. Br. J. Cancer, 28:285-298, 1973.

• 21) Heppner, G. H., Griswold, D. E., Lorenzo, J. D., Poplin, E. A. and Calabresi, P.:Selective immunosuppression by drugs in balanced immune responses. Fed. Proc., 33:1882-1885, 1974.

• 22) Mathe, G., Halle-Pannenko, O. and Bourut, C.:Immune manipulation by BCG administered before or after cyclophosphamide for chemoimmunotherapy of L1210 leukaemia. Europ. J. Cancer, 10:661-666, 1974.

• 23) Balow, J. E., Hurley, D. L. and Faucil, A. S.:Cyclophosphamide suppression of established cell mediated imrnunity. Quantitative vs. qualitative changes in lymphocyte populations. J. Clin. Invest., 56:65-70, 1975.

• 24) Fisher, B., Wolmark, N., Saffer, E., and Fisher, E. R.:Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors. Cancer, 35:134-143, 1975.
  pubmed

• 25) Debre, P., Waltenbaugh, C., Dorf, M. E. and Benacerraf, B.:Genetic control of specific immune suppression. IV. Responsiveness to the random copolymer L-glutamic acid-L-tyrosine induced in BALB/c by cyclophosphamide. J. Exp. Med., 144:277-281, 1976,

• 26) Gotohda, E., Kawamura, T., Sendo, F., Nakayama, M., Akiyarna, J., Oikawa, T., Hosokawa, M., Kodama, T. and Kobayashi, H.:Effect of combination treatment with cyclophosphamide and nonspecific passive immunization on a transplantable tumor in WKA rats. Cancer Res., 36:2119-2123, 1976.

• 27) Akiyama, J., Kawamura, T., Gotohda, E., Yamada, Y., Hosokawa, M., Kodama, T. and Kobayashi, H.:Immunochemotherapy of transplanted KMT-17tumor in WKA rats by combination of cyclophosphamide and immunostimulatory protein-bound polysaccharide isolated from basidiomycetes. Cancer Res., 37:3042-3045, 1977.

• 28) Balow, J. E., Parrillo, J. E. and Faucil, A. S.:Characterization of the direct effects of cyclophosphamide on cell-mediated immunological responses. Immunol., 32:899-904, 1977.

• 29) Chang, T., Stutzman, L. and Sokal, J. E.:Correlation of delayed hypersensitivity responses with chemotherapeutic results in advanced Hodgkins disease. Cancer, 36:950-955, 1977.

• 30) Kolb, J-P, B., Poupon, M-F, M., Lespinats, G. M., Sabolovic, D. and Loisillier, F.:Splenic modifications induced by cyclophosphamide in C3H /He, nude, and "B"-mice. J. Immunol., 118:1595-1599, 1977.

• 31) Neta, R., Winkelstein, A., Salvin, S. B. and Mendelow, H.:The effect of cyclophosphamide on suppressor cells in guinea pigs. Cell. Immuno., 33:402-411, 1977.

• 32) Noonan, F. P., Halliday, W. J., Wall, D. R. and Clunie, G. J. A.:Cell-mediated Immunity and serum blocking factors in cancer patients during chemotherapy and immunotherapy. Cancer Res., 39:2473-2480, 1977.

• 33) Orgel, H. A., Hamburger, R. N, Mendelson, L. M, Miller, J. R. and Kung, F. H.:Antibody responses in normal infants and in infants receiving chemotherapy for congenital neuroblastoma. Cancer, 40:994-997, 1977.
  pubmed

• 34) Sansing, W. A., Killion, J. J. and Kollmorgen, G. M.:Evaluation of time and dose in treating mammary adenocarcinoma with immunostimulants. Cancer Immunol. Immunother., 2:63-68, 1977.

• 35) Blomgren, H., Berg, H. J. V. Edsmyr, F., Norberg, R. and Wasserman, J.:Bleomycin treatment in a case of polyarteritis nodosa. Acta Med. Scand., 203:327-332, 1978.

• 36) Hellstrom, I., and Hellstrom, K. E.:Cyclophosphamide delays 3-methyl-cholanthrene sarcoma induction in mice. Nature, 275:129-130, 1978.

• 37) Hurwitz, E., Maron, R., Bernstein, A., Wilcheck, M., Sela, M. and Arnon, R.:The effect in vivo of chemotherapeutic drug antibody conjugates in two murine experimental tumor system. Int. J. Cancer, 21:747-755, 1978.

• 38) Kataoka, T., Kobayashi, H. and Sakurai, Y.:Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents. Cancer Res., 38 :1202-1207, 1978.
  pubmed

• 39) Lee, F. H., Berczi, I., Fujimoto. S. and Sehon, A. H.:The use of antifibrin antibodies for the destruction of tumor cells. III. Complete regression of MC-D sarcoma in guinea-pigs by conjugates of daunomycin with antifibrin antibodies. Cancer Immunol. Immunother., 5:201-206, 1978.

• 40) Nordman. E., Saarimaa, H. and Toivanen, A.:The influence of 5-fluorouracil on cellular and humoral immunity in cancer patients. Cancer, 41:64-69, 1978.
  pubmed

• 41) Schwartz, A., Askenase, P. W. and Gershon, R. K.:Regulation of delayed-type hypersensitivity reactions by cyclophosphamide sensitive T cells. J. Immunol., 121:1573-1576, 1978.
  pubmed

• 42) Dimitrov, N. V., Denny, T. N., Weisman, M. F. and Cameron, D. G.:Effect of adriamycin and Corynebacterium parvum in tumor-bearing mice:modulation of response to sheep red blood cells. J. Natl. Cancer Inst., 63:432-426, 1979.

• 43) Radley, J. M. and Scurfield, G.:Effects of 5-fluorouracil on mouse bone marrow. Br. J. Haem., 43:341-351, 1979.

• 44) Scott, M. T.:Analysis of the principles underlying chemo-immunotherapy of mouse tumours. I. Treatment with cyclophosphamide followed by Corynebacterium parvum. Cancer Immunol. Immunother., 6:107-112, 1979.

• 45) Stoychkov, J. N., Schultz, R. M., Chirigos, M. A., Pavlidis, N. A. and Goldin, A.:Effects of adriamycin and cyclophosphamide treatment on induction of macrophage cytotoxic function in mice. Cancer Res., 39:3014-3017, 1979.
  pubmed

• 46) Laitif, Z. A., Lozzio, B. B., Wust, C. J., Krauss, S., Aggio, M. C. and Lozzio, C. B.:Evaluation of drug-antibody conjugates in the treatment of human myelosarcomas transplanted in nude mice. Cancer, 45:1326-1333, 1980.

• 47) Santoni, A., Riccardi, C., Sorci, V. and Herberman, R. B.:Effects of adriamycill oll the activity of mouse natural killer cells. J. Immunol, 124:2329-2335, 1980.

• 48) Teller, M. N. and Faanes, R. B.:Association of host immunity with 5 fluorouracil-initiated cure of plasmacytoma LPG-1 in BALB/c mice. Cancer Res., 40:2790-2795, 1980.

• 49) Tomazic, V., Ehrke, M. J. and Mihich, E.:Modulation of the cytotoxic response against allogeneic tumor cells in culture by adriamycin. Cancer Res., 40:2748-2755, 1980.
  pubmed

• 50) Von Blomberg, B. M. E., Glerum, J., Croles, J. J., Stam, and Drexhage, H. A.:Harmful effects of I. V. Corynebacterium parvum given at the same time as cyclophosphamide in patients with squamous-cell carcinoma of the bronchus. Br. J. Cancer, 41:609-617, 1980.

• 51) Kawamura, T. Gotohda, E., Yamada, Y., Akiyama, J., Hosokawa, M., Kodama, T., and Kobayashi, H.:Tumor regression and enhancement caused by the time interval between cyclophosphamide administration and allogeneic lymphoid cell transfer. Cancer Res., submitted.

27. 癌の免疫学的予防

P.316 掲載の参考文献

• 1) 中野陽典, 田口鉄男, 鄭則之, 北村正次, 斉藤健一, 冨永健:抗腫蕩性蛋白糖PSK添加食のDMBA乳腺腫瘍発生に対する影響. 医学のあゆみ, 99:11-12, 1976.

• 2) 志方俊夫:予防ワクチンによるB型肝炎の予防. 内科, 46:278-283, 1980.

• 3) Old, L. J., Benacerraf, B., Clarke, C. A., Carswell, E. A. and Stockert, E.:The role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res., 21:1281-1300, 1961.

• 4) Deichman, G. I. and Kluchareva, T. E.:Immunological determinants of oncogenesis in hamsters infected with SV40 virus. Virol., 24:131-137, 1964.

• 5) Eddy, B. E., Grubbs, G. E. and Young, R. D.:Tumor immunity in hamsters infected with adenovirus type 12 or simian virus 40. Proc. Soc. Expl. Biol. Med., 117:575-779, 1964.

• 6) Lemonde, P. and Clode-Hyde, M.:Influence of Bacillus Calmette-Guerin infection on polyoma in hamsters and mice. Cancer Res., 26:585-589, 1966.
  pubmed

• 7) Sjogren, H. O. and Ankerst, J.:Effect of BCG and allogeneic tumor cells on adenovirus type 2 tumorigenesis in mice. Nature, 221:863-864, 1969.

• 8) Davignon, L., Lemonde, P., Robillard, P. and Frappier, A.:BCG vaccination and leukaemia mortality. Lancet, ii:638, 1970.

• 9) Piessens, W. F., Lachapelle, F. L., Legros, N. and Henson, J. -C:Facilitation of rat mammary tumor growth by BCG. Nature, 228:1310-1311, 1970.

• 10) Comstock, G. W., Livesay, V. T. and Webster, R. G.:Leukemia and BCG. Lancet, ii:1062-1063, 1971.

• 11) Kinlen, L. J. and Pike, M. C.:BCG vaccination and leukaemia:Evidence of vital statistics. Lancet, ii:398-402, 1971.

• 12) Larson, C. L., Ushijima, R. N., Florey, M H., Baker, R. E. and Baker, M. B.:Effect of BCG on Friend disease virus in mice. Nature, New Biol., 229:243-244, 1971.

• 13) Mann, D. L., Rogentine, G. N., Halterman, R.:Detection of an antigen associated with leukemia. Science, 24:1136-1137, 1971.

• 14) Schwartz, D. B., Zbar, B., Gibson, W. T. and Chirigos, M. A.:Inhibition of murine sarcoma virus oncogenesis with living BCG. Int. J. Cancer, 8:320-325, 1971.
  pubmed

• 15) Ankerst, J. and Johnson, N.:Inhibitory effects of BCG on adenovirus tumorigenesis;dependence on administration schedule. Int. J. Cancer, 10:351-356, 1972.

• 16) Larson, C. L, Ushijima, R. N., Karim, R., Baker, M. B. and Baker, R. E.:Herpesvirus homnis type 2 infections in rabbits:Effect of prior immunization with attenuated Mycobaterium bovis (BCG) cells. Infect. Immunity, 6:465-468, 1972.

• 17) Morton, D. L.:Immunotherapy of cancer. Present status and future potential. Cancer, 30:1647-1655, 1972.
  pubmed

• 18) Prehn, R. T.:The immune reaction as a stimulator of tumor growth. Science, 176:170-171, 1972.
  pubmed

• 19) Rosenthal, S. R.:BCG vaccination and leukemia mortality. J. A. M. A., 222:1543-1544, 1972.
  pubmed

• 20) Taranger, L. A., Chapman, W. H., Hellstrom, I. and Hellstrom, K. E.:Immunological studies on urinary bladder tumors of rats and mice. Science, 176:1337-1340, 1972.
  pubmed

• 21) Whitmire, C. E and Huebner, R. J.:Inhibition of chemical carcinogenesis by viral vaccines. Science, 177:60-61, 1972.
  pubmed

• 22) Tokunaga, T., Kataoka, T., Nakamura, M. R., Yamamoto, S. and Murakoshi, T.:Immunotherapeutic effects of BCG on autochthonous tumors induced with MCA in mice. Proc. 8th Joint Conf. Tuberc., U. S. -Japan Cooperative Med. Sci. Prog., p. 129-150, 1973.

• 23) Check, J. H., Brady, L. W., Leipold, P. L. and O'Neill, E. A.:Protection against transplanted and spontaneous lymphoma by inoculation of heat-altered syngeneic tumor cells in splenectomized mice. Cancer, 34:197-203, 1974.

• 24) Gozzo, J. J., Schlesinger, R. M. and Monace, A. P.:Detection of bladder-cancer-associated antigen in urine by micro-complement fixation. Surg. Forum, 25:117-119, 1974.

• 25) Hollinshead, A. C., Stewart, T. H. M. and Herberman, R. B.:Delayed hypersensitivity reactions to soluble membrane antigells of human malignant Iung cells. J. Natl. Cancer Inst., 55:327-338,

• 26) Takeichi, N., Kuzumaki, N., Kodama, T and Kobayahi, H.:Break-down of Gross virus-induced tolerance in rats by inoculation of lymphoid cells. J. Natl. Cancer Inst., 52:1817-1822, 1974.

• 27) Debre, P., Waltenbauch, C., Dorf, M. E. and Benacrraf, B.:Genetic control of specific immune suppression. IV. Responsiveness to the random copolymer L-glutamic acid-L-tyrosine induced in BALB/c by cyclophosphamide. J. Exp. Med., 144:277-281, 1976.

• 28) Leffell, M. S., and Coggin, J. H. Jr:Common transplantatioll antigens on methylcholanthrene-induced murine sarcomas detected by three assays of tumor rejection. Cancer Res. 37:4112-4119, 1977.
  pubmed

• 29) Cruse, J. P., Lewin, M. R., and Clark, C. G.:Corynebacterium parvum enhances colonic cancer in dimethylhydrazine-treated rats. Br. J. Cancer, 37 :639-643. 1978.
  pubmed

• 30) Hellstrom, I. and Hellstrom, K. E.:Cyclophosphamide delays 3-methyl-cholanthrene sarcoma induction in mice. Nature, 275:129-130, 1978.

• 31) Hirao, F., Nishikawa, H., Yasaki, S., Ohura, T., Azuma. I., Taniyama. T., Yoshimoto, T., Kijimoto, S. and Yamamura, Y.:Effect of oil-attached BCG cell-wall skeleton and thymectomy on the incidence of lung cancer and amyloidosis induced by chemical carcinogens in rabbits. Gann. 69:453-459. 1978.

• 32) Fujita, K., Fujita, H., Suzuki, K, Tajima A. and Aso, T.:Effect of Krestin on bladder tumor induction in rats by N-butyl-N- (4-hydroxybutyl) nitrosamin. Acta Urol. J ap., 25:917-920, 1979.

• 33) Namba, M., Yoshimoto, T., Ogura, T., Hirao, F., Azuma, I. and Yamamura, Y.:Effect of Nocardia rubra cell-wall skeleton on the induction of lung cancer in ACI/N rats. Gann, 70:55-62, 1979.

• 34) Inoue, T., Yoshimoto, T., Ogura, T., Hirao, F. and Yamamura, Y.:Timing of Nocardia rubra cell-wall skeleton (N-CWS) treatment in two stage chemical carcinogenesis of mouse skin. Proc. J ap. Cancer Assoc., 39:70, 1980.

• 35) Ishioka, S., Yamakido, M., Onari, K., Takaichi, M., Sadamoto, K. and Nishimoto, Y.:Changes of NK cell activity, ADCC activity, PHA cellular cytotoxicity and PHA response of peripheral lymphocytes before and after Nocardia CWS injection in the retired workers of Okunojima poison gas factory. Proc. J ap. Cancer Assoc., 39:85, 1980.